[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2159
1. Chen YY, DeVries S, Anderson J, Lessing J, Swain R, Chin K, Shim V, Esserman LJ, Waldman FM, Hwang ES: Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ. BMC Cancer; 2009 Aug 18;9:285
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.
  • BACKGROUND: Endocrine therapy is commonly recommended in the adjuvant setting for patients as treatment for ductal carcinoma in situ (DCIS).
  • However, it is unknown whether a neoadjuvant (preoperative) anti-estrogen approach to DCIS results in any biological change.
  • This study was undertaken to investigate the pathologic and biomarker changes in DCIS following neoadjuvant endocrine therapy compared to a group of patients who did not undergo preoperative anti-estrogenic treatment to determine whether such treatment results in detectable histologic alterations.
  • METHODS: Patients (n = 23) diagnosed with ER-positive pure DCIS by stereotactic core biopsy were enrolled in a trial of neoadjuvant anti-estrogen therapy followed by definitive excision.
  • Following treatment, predominant morphologic changes included increased multinucleated histiocytes and degenerated cells, decreased duct extension, and prominent periductal fibrosis.
  • Two postmenopausal patients had ADH only with no residual DCIS at excision.
  • Two patients had invasive cancer at surgery.
  • CONCLUSION: Preoperative therapy for DCIS is associated with significant pathologic alterations.
  • Further work is needed to identify which women may be the best candidates for such treatment for DCIS, and whether best responders may safely avoid surgical intervention.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Estrogen Antagonists / therapeutic use. Hormone Replacement Therapy. Receptors, Estrogen / metabolism. Tamoxifen / therapeutic use
  • [MeSH-minor] Adult. Aged. Carcinoma, Ductal. Cohort Studies. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Nitriles / therapeutic use. Triazoles / therapeutic use

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. LETROZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):616-21 [10690547.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):45-53 [18083636.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4284-8 [10945643.001]
  • [Cites] Radiology. 2000 Nov;217(2):466-70 [11058647.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5995-6000 [11085519.001]
  • [Cites] Radiology. 2001 Feb;218(2):497-502 [11161168.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):961-6 [11535548.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6739-46 [11559545.001]
  • [Cites] Ann Oncol. 2001 Nov;12(11):1527-32 [11822750.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1026-35 [11844826.001]
  • [Cites] J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):103-7 [11850213.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45695-703 [12244117.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):277-83 [12865917.001]
  • [Cites] N Engl J Med. 2004 Apr 1;350(14):1430-41 [15070793.001]
  • [Cites] Cancer. 1984 Aug 15;54(4):612-5 [6744199.001]
  • [Cites] Br J Cancer. 1985 Feb;51(2):271-8 [3966983.001]
  • [Cites] Arch Pathol Lab Med. 1985 Aug;109(8):716-21 [3893381.001]
  • [Cites] Br J Cancer. 1987 Dec;56(6):814-9 [2829956.001]
  • [Cites] N Engl J Med. 1989 Feb 23;320(8):479-84 [2644532.001]
  • [Cites] Hum Pathol. 1992 Oct;23(10):1095-7 [1328030.001]
  • [Cites] Br J Cancer. 1993 Mar;67(3):606-11 [8439511.001]
  • [Cites] Histopathology. 1993 Sep;23(3):233-8 [8225241.001]
  • [Cites] Semin Diagn Pathol. 1994 Aug;11(3):223-35 [7831534.001]
  • [Cites] JAMA. 1996 Mar 27;275(12):913-8 [8598618.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1197-200 [8630897.001]
  • [Cites] Breast Cancer Res Treat. 1996;41(1):31-41 [8932874.001]
  • [Cites] Int J Cancer. 1997 Aug 7;72(4):608-13 [9259399.001]
  • [Cites] Int J Oncol. 1998 Apr;12(4):853-8 [9499446.001]
  • [Cites] Lancet. 1999 Jun 12;353(9169):1993-2000 [10376613.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):951s-8s [15701892.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2477-92 [15767642.001]
  • [Cites] Cancer. 2005 May 1;103(9):1778-84 [15770688.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):2980-7 [15860853.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2481-4 [15884091.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5108-16 [15998903.001]
  • [Cites] N Engl J Med. 2005 Dec 29;353(26):2747-57 [16382061.001]
  • [Cites] Cancer. 2006 May 15;106(10):2095-103 [16598749.001]
  • [Cites] Breast Cancer Res Treat. 2006 May;97(2):135-44 [16319971.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):173-9 [17604618.001]
  • [Cites] Arch Intern Med. 2000 Apr 10;160(7):953-8 [10761960.001]
  • (PMID = 19689789.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00290745
  • [Grant] United States / NCI NIH HHS / CA / K23CA097181; United States / NCI NIH HHS / CA / P50 CA58207
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 0 / Nitriles; 0 / Receptors, Estrogen; 0 / Triazoles; 094ZI81Y45 / Tamoxifen; 7LKK855W8I / letrozole
  • [Other-IDs] NLM/ PMC2744704
  •  go-up   go-down


2. Paepke S, Schmid R, Fleckner S, Paepke D, Niemeyer M, Schmalfeldt B, Jacobs VR, Kiechle M: Subcutaneous mastectomy with conservation of the nipple-areola skin: broadening the indications. Ann Surg; 2009 Aug;250(2):288-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • If the breast gland tissue and all milk ducts can be separated completely from the nipple-areola skin (NA-skin) during subcutaneous mastectomy (SCM), conservation of the NA-skin is feasible even in the case of large, central, and retroareolar tumors.
  • Total mastectomy was indicated in 94 of these breasts, in 16 because of extensive ductal carcinoma in situ, and 78 breasts with invasive carcinoma required additional axillary dissection resulting in indication for modified radical mastectomy.
  • After dissection of all the breast tissue, the skin envelope with the areola is turned inside out and all milk ducts and any tissue beneath the areola are precisely dissected under the surgeon's visual control.
  • The remaining contraindications for SCM are: extensive tumor involvement of the skin, inflammatory breast cancer, and a clinically suspicious nipple.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma, Ductal, Breast / surgery. Carcinoma, Intraductal, Noninfiltrating / surgery. Mastectomy, Subcutaneous / methods
  • [MeSH-minor] Cohort Studies. Disease-Free Survival. Female. Humans. Mammaplasty. Patient Selection. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19638905.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00641628
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Onesti JK, Mangus BE, Helmer SD, Osland JS: Breast cancer tumor size: correlation between magnetic resonance imaging and pathology measurements. Am J Surg; 2008 Dec;196(6):844-48; discussion 849-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer tumor size: correlation between magnetic resonance imaging and pathology measurements.
  • BACKGROUND: As physicians increasingly use magnetic resonance imaging (MRI) for the evaluation of newly diagnosed breast cancers, a review of the correlation between MRI and pathology tumor size is imperative.
  • METHODS: A retrospective review of 91 breast tumors comparing preoperative MRI tumor size to final pathology tumor size was performed.
  • This trend continued for the histological subtypes of ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), and invasive lobular carcinoma (ILC).
  • Clinicians should therefore use caution in relying on MRI tumor size in determining candidacy for breast conservation therapy (BCT).
  • [MeSH-major] Breast Neoplasms / pathology. Magnetic Resonance Imaging / methods. Neoplasm Staging / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Reproducibility of Results. Retrospective Studies. Severity of Illness Index

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19095098.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Visscher DW: Apocrine ductal carcinoma in situ involving a sclerosing lesion with adenosis: report of a case. Arch Pathol Lab Med; 2009 Nov;133(11):1817-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine ductal carcinoma in situ involving a sclerosing lesion with adenosis: report of a case.
  • Dramatic apocrine atypia may be very difficult to distinguish from apocrine ductal carcinoma in situ.
  • Herein, I report a case in which apocrine ductal carcinoma in situ presented as "atypical apocrine adenosis" in a needle core breast biopsy.
  • It illustrates the problem of assessing apocrine atypia and apocrine ductal carcinoma in situ in small samples.
  • [MeSH-major] Apocrine Glands / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Fibrocystic Breast Disease / pathology. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886717.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Khalbuss WE, Ambaye A, Goodison S, Loya A, Masood S: Papillary carcinoma of the breast in a male patient with a treated prostatic carcinoma diagnosed by fine-needle aspiration biopsy: a case report and review of the literature. Diagn Cytopathol; 2006 Mar;34(3):214-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary carcinoma of the breast in a male patient with a treated prostatic carcinoma diagnosed by fine-needle aspiration biopsy: a case report and review of the literature.
  • Papillary carcinoma of the male breast is very rare.
  • In this case report, we describe the cytologic, histologic, immunohistochemical, and radiological findings of a papillary carcinoma of male breast.
  • A 67-yr-old man, who had a previous history of prostatic adenocarcinoma, presented with a retroareolar painless mass.
  • There was no known history of breast cancer in his family.
  • A diagnosis of papillary lesion favoring papillary carcinoma was rendered.
  • The patient underwent lumpectomy, which showed a moderately differentiated infiltrating papillary carcinoma with adjacent areas of ductal carcinoma in situ.
  • FNAB is a useful technique in identifying male breast carcinoma.
  • [MeSH-major] Adenocarcinoma / therapy. Breast Neoplasms, Male / pathology. Carcinoma, Papillary / pathology. Neoplasms, Second Primary / pathology. Prostatic Neoplasms / therapy
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Mammaglobin A. Neoplasm Metastasis. Neoplasm Proteins / analysis. Prostate-Specific Antigen / analysis. Uteroglobin / analysis

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):446-9 [8621225.001]
  • [Cites] Cancer Res. 1995 Mar 1;55(5):1002-5 [7866981.001]
  • [Cites] Pathology. 1997 Feb;29(1):2-6 [9094169.001]
  • [Cites] J Mol Med (Berl). 1997 Oct;75(10):758-61 [9383000.001]
  • [Cites] Indian J Pathol Microbiol. 1998 Jan;41(1):103-6 [9581085.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):498-509 [9690543.001]
  • [Cites] Acta Cytol. 1999 Sep-Oct;43(5):767-70 [10518128.001]
  • [Cites] Cancer. 1962 May-Jun;15:444-55 [14459407.001]
  • [Cites] Breast J. 2003 May-Jun;9(3):208-12 [12752629.001]
  • [Cites] Diagn Cytopathol. 2003 Jun;28(6):329-34 [12768640.001]
  • [Cites] Arch Pathol Lab Med. 1986 Mar;110(3):189-91 [3080975.001]
  • [Cites] Tumori. 1986 Feb 28;72(1):105-8 [3952817.001]
  • [Cites] Diagn Cytopathol. 1991;7(6):581-90 [1769286.001]
  • [Cites] Am J Epidemiol. 1992 Apr 1;135(7):734-48 [1350708.001]
  • [Cites] Int J Cancer. 1993 Jan 21;53(2):269-77 [8425764.001]
  • [Cites] Acta Cytol. 1993 Sep-Oct;37(5):721-4 [8362586.001]
  • [Cites] Diagn Cytopathol. 1994;10(4):336-41 [7924806.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):860-5 [8631025.001]
  • (PMID = 16548002.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108597
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 18
  • [Other-IDs] NLM/ NIHMS399894; NLM/ PMC3428056
  •  go-up   go-down


6. McLaughlin SA, Stempel M, Morris EA, Liberman L, King TA: Can magnetic resonance imaging be used to select patients for sentinel lymph node biopsy in prophylactic mastectomy? Cancer; 2008 Mar 15;112(6):1214-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Occult cancer was identified in 33 of 613 PMs (5%) (10 invasive and 23 ductal carcinoma in situ cases).
  • Of these, occult cancer was found in 6 of 178 patients (3%), all of whom had negative SLNB.
  • Preoperative MRI was concordant with PM in 4 of 6 cases with occult carcinoma.
  • Occult cancer was found in 18 of 215 patients (8%); 3 had positive SLNB.
  • MRI detected 5 cancers and PM revealed an additional 4 occult carcinomas not detected by MRI.
  • Overall, 9 of 136 patients (7%) undergoing PM alone were found to have occult cancer, 3 of which were invasive, raising the decision of reoperation with ALND.
  • CONCLUSIONS: Occult cancer was identified in 5% of PMs.
  • PM with or without SLNB spared only 4 of 393 patients (1%) from undergoing ALND, whereas PM alone identified unsuspected invasive disease in 3 of 136 patients (2%).
  • When performed, MRI accurately ruled out the presence of an invasive cancer in the prophylactic breast, suggesting that MRI can be used to select patients for PM without SLNB.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Magnetic Resonance Imaging / methods. Mastectomy. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Aged. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Intraductal, Noninfiltrating / surgery. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / surgery. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness / diagnosis. Neoplasm Staging. Preoperative Care. Prospective Studies. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • (PMID = 18257089.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Oprić D, Granić M, Mujkanović N, Oprić S, Malis M: [Breast Paget disease: morphologic substrate and Paget cells characteristics]. Med Arh; 2006;60(3):171-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast Paget disease: morphologic substrate and Paget cells characteristics].
  • Authors analyzed 143 cases of breast Paget disease with special emphasis on basic tumor process and on immune histochemical characteristics of tumor cells.
  • Breast Paget disease represent special clinical presentation of the breast tumor.
  • The most often tumor in the breast are ductal carcinoma in situ, ductal carcinoma and in rare instance lobular carcinoma and lobular carcinoma in situ.
  • The best prognosis is in cases with in situ as underlying process.
  • All other combinations have worse prognosis in relation to the combination with in situ lesion.
  • The middle ages of patients with Paget disease is 10 years higher than the ages without areola involvement.
  • [MeSH-major] Breast Neoplasms / pathology. Paget's Disease, Mammary / pathology

  • Genetic Alliance. consumer health - Paget Disease.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16719231.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] bos
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


8. Intra M, Soteldo J, Bassani G: Sentinel lymph node biopsy in ductal carcinoma in situ of the male breast. Breast J; 2005 Mar-Apr;11(2):154
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node biopsy in ductal carcinoma in situ of the male breast.
  • [MeSH-major] Breast Neoplasms, Male / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Sentinel Lymph Node Biopsy

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Breast J. 2004 May-Jun;10(3):263-4 [15125759.001]
  • (PMID = 15730470.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


9. Planas J, Morote J, Orsola A, Salvador C, Trilla E, Cecchini L, Raventós CX: The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU Int; 2007 Apr;99(4):812-5; discussion 815-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship between daily calcium intake and bone mineral density in men with prostate cancer.
  • OBJECTIVE: To analyse the relationship between daily calcium intake (DCI) and bone mineral density (BMD) in patients with prostate cancer, and to assess if DCI is a risk factor for osteoporosis in this group of patients.
  • PATIENTS AND METHODS: DCI was assessed by a standard questionnaire answered by men with prostate cancer who had had bone densitometry.
  • BMD was measured by dual-energy X-ray absorptiometry in the lumbar spine and different hip sites, in a cross-sectional study including 372 men with prostate cancer free of bone metastases, 71.5% (266) under androgen-deprivation therapy (ADT) and 28.5% (106) after radical prostatectomy (RP).
  • Osteoporosis was defined according to the International Society for Clinical Densitometry official position (2005).
  • RESULTS: A DCI of <1000 mg, the National Institute of Health recommendation, was detected in 93% of the men, (93.5% under ADT and 91.5% after RP).
  • The mean DCI was 609.7 mg in men with osteoporosis and 682.8 mg in those without (P < 0.001); in men under ADT the mean DCI remained significantly lower in those with osteoporosis (615.5 vs 700.4 mg, P < 0.001).
  • A multivariate analysis showed that DCI was an independent risk factor for osteoporosis, together with patient age, ADT and its duration.
  • CONCLUSIONS: DCI seems to be related to BMD; a low DCI was an independent risk factor for osteoporosis in men with prostate cancer.
  • In the study population overall the DCI was inadequate.
  • Urologists should recommend a DCI of >1000 mg in patients with prostate cancer, especially in those under ADT.


10. Chuwa EW, Tan VH, Tan PH, Yong WS, Ho GH, Wong CY: Treatment for ductal carcinoma in situ in an Asian population: outcome and prognostic factors. ANZ J Surg; 2008 Jan-Feb;78(1-2):42-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment for ductal carcinoma in situ in an Asian population: outcome and prognostic factors.
  • BACKGROUND: Breast cancer is the most common cancer among Singapore women and ductal carcinoma in situ (DCIS) is believed to be the precursor of most invasive breast cancers.
  • The incidence of DCIS has increased dramatically with mammographic screening, but its treatment remains controversial.
  • Further, results of treatment for DCIS in Asians, and in particular Singapore women, are lacking.
  • We review our institution's results treating a predominantly Chinese population with DCIS of the breast before the introduction of mammographic screening and aim to determine treatment outcomes and identify prognostic factors for disease recurrence.
  • METHODS: Between January 1994 and December 2000, 170 consecutive patients with DCIS were treated at our institution.
  • One hundred and three (60.5%) were managed with breast conservation (17 with local wide excision alone and 86 with adjuvant irradiation following wide excision) whereas 67 (39.4%) underwent mastectomy.
  • Patients who underwent breast conservation surgery had oncologically more favourable lesions - with a significantly higher incidence of smaller and non-palpable lesions and lesions of lower nuclear grade.
  • At the end of follow up, there were 12 patients (7.1%) who developed local recurrence and 8 patients (4.7%) developed contralateral disease.
  • The crude incidence of all breast events (including both local failure and contralateral events) at 5 years was 5.6%.
  • Median time to the development of any breast event (local recurrence or contralateral disease) was 60 months (range 12-120 months).
  • The cumulative 5-year recurrence-free survival for patients who underwent breast conservation surgery was 94%.
  • There were no cancer-specific deaths during the period of follow up.
  • CONCLUSION: Our results indicate that rates of cancer-specific survival were similar after mastectomy and breast conserving surgery.
  • Our results reinforce that optimizing local therapy is crucial to improve local control rates in women treated with DCIS in our population.
  • [MeSH-major] Asian Continental Ancestry Group. Breast Neoplasms / epidemiology. Breast Neoplasms / therapy. Carcinoma, Intraductal, Noninfiltrating / epidemiology. Carcinoma, Intraductal, Noninfiltrating / therapy. Mastectomy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18199204.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


11. Fernandopulle SM, Cher-Siangang P, Tan PH: Breast carcinoma in women 35 years and younger: a pathological study. Pathology; 2006 Jun;38(3):219-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast carcinoma in women 35 years and younger: a pathological study.
  • AIMS: To document the pathological features of breast carcinoma diagnosed in women aged 35 years or less.
  • METHODS: The files of the Department of Pathology, Singapore General Hospital, were searched for cases of breast cancer diagnosed in individuals aged 35 years or less between January 1993 and December 2004.
  • Pathologic parameters of tumour size, histological grade, accompanying ductal carcinoma in situ (DCIS), lymphovascular invasion, nodal status, hormone receptor and c-erbB-2 profiles, were documented.
  • RESULTS: Of 112 cases of breast cancer, 91 (81.3%) were invasive carcinomas, 17 (15.2%) pure DCIS, three (2.7%) were diagnosed on needle aspirates.
  • Invasive tumour size ranged from 0.3 to 11.5 cm (mean 2.7 cm, median 2.1 cm), with 84 (92.3%) infiltrative ductal, two (2.2%) lobular, two (2.2%) mucinous, two (2.2%) atypical medullary, and one (1.1%) mixed ductal-lobular.
  • Oestrogen and progesterone receptors (ER, PR) were positive in 51 (61.4%) and 43 (51.8%) cases, respectively, out of 83 (91.2%) cases in which they were evaluated. c-erbB-2 immunostaining, carried out in 54 (59.3%) invasive cancers, showed positivity in 16 (29.6%) cases.DCIS cases ranged from 0.25 to 6.2 cm (mean 2.2 cm, median 2 cm) in size.
  • CONCLUSION: The majority of breast carcinomas in young women are invasive, with T2 disease at presentation, and of poor histological grade.
  • The recent rise in numbers suggests increased detection, plausibly due to improved awareness of breast disease among the younger female population.
  • Pathogenetic causes that differ from breast carcinogenesis in older women have to be further clarified.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753742.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


12. Jin JS, Cheng TF, Tsai WC, Sheu LF, Chiang H, Yu CP: Expression of the serine protease, matriptase, in breast ductal carcinoma of Chinese women: correlation with clinicopathological parameters. Histol Histopathol; 2007 03;22(3):305-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the serine protease, matriptase, in breast ductal carcinoma of Chinese women: correlation with clinicopathological parameters.
  • Matriptase is a serine protease expressed by cells of surface epithelial origin, including epithelial breast tumor cells.
  • Matriptase cleaves and activates proteins implicated in the progression of cancer and represents a potential prognostic and therapeutic target.
  • The aim of this study was to examine matriptase expression in breast tumors of Chinese women and to identify its clinicopathological correlations.
  • Immunohistochemical analysis of matriptase was performed in tissue microarrays of 251 breast tumors including 30 fibroadenomas, 59 ductal carcinomas in situ (DCIS), 38 grade I invasive ductal carcinomas (IDC), 79 grade II IDC, and 45 grade III IDC.
  • The matriptase scores were significantly higher in the tumors than their non-tumor counterparts (178+/-12 for fibroadenoma; 275+/-11 for DCIS; 299+/-10 for grade I IDC; 251+/-10 for grade II IDC; and 314+/-11 for grade III IDC).
  • Our findings demonstrate that matriptase is over-expressed in breast ductal carcinoma of Chinese women.
  • It therefore may be a good biomarker for diagnosis and treatment of malignant breast tumors.
  • [MeSH-major] Breast Neoplasms / enzymology. Carcinoma, Ductal, Breast / enzymology. Carcinoma, Intraductal, Noninfiltrating / enzymology. Fibroadenoma / enzymology. Serine Endopeptidases / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. China / ethnology. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Taiwan / epidemiology. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17163404.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.- / Serine Endopeptidases
  •  go-up   go-down


13. Duchesne N, Parker SH, Lechner MC, Gittleman MA, Kusnick CA, Elvecrog EE, Kaske TI, Gizienski TA: Multicenter evaluation of a new ultrasound-guided biopsy device: Improved ergonomics, sampling and rebiopsy rates. Breast J; 2007 Jan-Feb;13(1):36-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter evaluation of a new ultrasound-guided biopsy device: Improved ergonomics, sampling and rebiopsy rates.
  • The purpose of this study was to evaluate performance, ergonomics, and immediate rebiopsy rate of a new vacuum-assisted biopsy (VAB) device for ultrasound-guided breast biopsies.
  • Patient and procedural data included breast composition, lesion characteristics, number of samples, procedure time, and complications.
  • One hundred thirteen patients aged 20-83 years (mean 52) were successfully biopsied with dense/fibrous breast tissue in 60% and dense/fibrous lesions in 49%.
  • Operators rated safety and comfort comparable with existing devices and rated sample quality, breast/lesion penetration, and positioning ease/accuracy superior (p < 0.01).
  • Diagnoses included 37 cancers, 70 benign, and six high-risk lesions with one upgrade from atypical ductal hyperplasia to ductal carcinoma in situ at surgery.
  • Compared with other devices, it is more ergonomic to target and position for sampling, particularly in dense breast tissue or lesions.
  • [MeSH-major] Biopsy / instrumentation. Breast Neoplasms / pathology. Ultrasonography, Interventional / instrumentation

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214791.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG: Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod Pathol; 2007 Jan;20(1):84-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade.
  • To date, only one study has addressed the clinical significance of stromal CD10 expression in invasive carcinoma of the breast.
  • The aim of this confirmatory study is to evaluate stromal CD10 expression in breast carcinoma and to examine associations between CD10, clinicopathological variables, and patient outcome.
  • Tissue microarrays, containing 438 cases of invasive breast carcinoma and 15 cases of ductal carcinoma in situ with 15 years median follow-up time, were assembled.
  • Stromal CD10 was preferentially expressed in invasive compared to noninvasive breast cancers (P=0.003).
  • There was no correlation between CD10 and lymph node status, tumor size, histological subtype, progesterone receptors, and Her2 status.
  • Stromal CD 10 expression was associated with decreased long-term disease-specific and overall survival in the entire cohort (P<0.01), and in lymph node negative (P<0.05), but not lymph node positive subset of patients.
  • Thus, stromal CD10 expression in invasive carcinoma of the breast is associated with ER negativity, higher tumor grade and decreased survival and constitutes a potential prognostic marker and a target for development of novel therapies.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Extracellular Matrix / pathology. Neprilysin / analysis. Receptors, Estrogen / analysis. Stromal Cells / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Follow-Up Studies. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymph Nodes / pathology. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Time Factors. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143263.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


15. Shamliyan T, Wang SY, Virnig BA, Tuttle TM, Kane RL: Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ. J Natl Cancer Inst Monogr; 2010;2010(41):121-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ.
  • We synthesized the evidence of the association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ of the breast.
  • Younger women with clinically presented ductal carcinoma in situ had higher risk of ipsilateral recurrent cancer.
  • African Americans had higher mortality and greater rates of advanced recurrent cancer.
  • [MeSH-major] Breast Neoplasms / epidemiology. Carcinoma, Intraductal, Noninfiltrating / epidemiology
  • [MeSH-minor] Adult. Age Factors. Aged. Body Mass Index. Continental Population Groups / statistics & numerical data. Female. Gonadal Steroid Hormones / adverse effects. Humans. Mammography. Menopause. Neoplasm Recurrence, Local / epidemiology. Neoplasms, Hormone-Dependent / chemistry. Neoplasms, Hormone-Dependent / epidemiology. Neoplasms, Hormone-Dependent / pathology. Neoplasms, Hormone-Dependent / therapy. Prognosis. Randomized Controlled Trials as Topic / statistics & numerical data. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Risk. Socioeconomic Factors. Treatment Outcome. Tumor Burden

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20956815.001).
  • [ISSN] 1745-6614
  • [Journal-full-title] Journal of the National Cancer Institute. Monographs
  • [ISO-abbreviation] J. Natl. Cancer Inst. Monographs
  • [Language] eng
  • [Grant] United States / PHS HHS / / 290-02-0009
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


16. Doren E, Hulvat M, Norton J, Rajan P, Sarker S, Aranha G, Yao K: Predicting cancer on excision of atypical ductal hyperplasia. Am J Surg; 2008 Mar;195(3):358-61; discussion 361-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predicting cancer on excision of atypical ductal hyperplasia.
  • BACKGROUND: There are no specific histopathologic factors that allow identification of patients with atypical ductal hyperplasia (ADH) who will have cancer on final excision.
  • Eight (15.7%) patients had invasive carcinoma on surgical excision, 9 (17.5%) had ductal carcinoma-in-situ (DCIS), 21 (41.5%) had ADH, 4 (8%) patients had atypical lobular hyperplasia, and 9 (17.5%) had benign tumors.
  • On multivariate analysis of histopathologic factors, the grade of atypia was the only significant variable that predicted a diagnosis of cancer on final surgical excision (P = .001).
  • CONCLUSIONS: The grade of atypia correlated with the presence of cancer on surgical excision.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18206849.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Whipple RA, Matrone MA, Cho EH, Balzer EM, Vitolo MI, Yoon JR, Ioffe OB, Tuttle KC, Yang J, Martin SS: Epithelial-to-mesenchymal transition promotes tubulin detyrosination and microtentacles that enhance endothelial engagement. Cancer Res; 2010 Oct 15;70(20):8127-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epithelial-to-mesenchymal transition (EMT) is associated with increased breast tumor metastasis; however, the specific mechanisms by which EMT promotes metastasis remain somewhat unclear.
  • Suppression of endogenous Twist in metastatic human breast tumor cells is capable of reducing both tubulin detyrosination and microtentacles.
  • Clinical breast tumor samples display high concordance between Glu-tubulin and Twist expression levels, emphasizing the coupling between EMT and tubulin detyrosination in vivo.
  • Coordinated elevation of Twist and Glu-tubulin at invasive tumor fronts, particularly within ductal carcinoma in situ samples, establishes that EMT-induced tubulin detyrosination occurs at the earliest stages of tumor invasion.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. L-TYROSINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] J Cell Biol. 1989 Nov;109(5):2275-88 [2681230.001]
  • [Cites] Oncogene. 2010 Jun 3;29(22):3217-27 [20228842.001]
  • [Cites] Biochemistry. 1992 Jun 30;31(25):5849-56 [1610827.001]
  • [Cites] Acta Anat (Basel). 1995;154(1):8-20 [8714286.001]
  • [Cites] J Cell Sci. 1998 Jan;111 ( Pt 2):171-81 [9405300.001]
  • [Cites] Biophys J. 2005 May;88(5):3689-98 [15722433.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5153-62 [15958559.001]
  • [Cites] Dev Dyn. 2005 Jul;233(3):706-20 [15937929.001]
  • [Cites] Eur J Cell Biol. 2006 Apr;85(3-4):213-8 [16546563.001]
  • [Cites] Prostate. 2006 Jun 15;66(9):954-65 [16541425.001]
  • [Cites] J Cell Biol. 2006 Sep 11;174(6):839-49 [16954346.001]
  • [Cites] Assay Drug Dev Technol. 2006 Oct;4(5):597-607 [17115930.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] Genes Cells. 2007 Apr;12(4):535-46 [17397400.001]
  • [Cites] Exp Cell Res. 2007 Apr 15;313(7):1326-36 [17359970.001]
  • [Cites] Pathology. 2007 Jun;39(3):305-18 [17558857.001]
  • [Cites] J Cell Physiol. 2007 Nov;213(2):374-83 [17680632.001]
  • [Cites] Int J Cancer. 2007 Nov 1;121(9):1941-8 [17631641.001]
  • [Cites] Cell. 2008 May 16;133(4):704-15 [18485877.001]
  • [Cites] Dev Cell. 2008 Jun;14(6):818-29 [18539112.001]
  • [Cites] Genes Dev. 2001 Jan 1;15(1):50-65 [11156605.001]
  • [Cites] J Pathol. 2008 Jul;215(3):330-9 [18491351.001]
  • [Cites] Clin Exp Metastasis. 2008;25(6):629-42 [18461285.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):5678-88 [18632620.001]
  • [Cites] Histochem Cell Biol. 2008 Sep;130(3):481-94 [18648847.001]
  • [Cites] Nat Methods. 2008 Dec;5(12):1019-21 [18997781.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5024-7 [11431336.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):30690-8 [12070174.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):921-30 [14737122.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Exp Cell Res. 2004 Sep 10;299(1):236-47 [15302590.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):365-75 [15382060.001]
  • [Cites] Cancer Res. 1982 Dec;42(12):5183-90 [7139623.001]
  • [Cites] J Cell Biol. 1987 Jul;105(1):251-64 [2886509.001]
  • [Cites] J Cell Biol. 1987 Jul;105(1):265-76 [3301867.001]
  • [Cites] J Cell Sci. 1987 Sep;88 ( Pt 2):185-203 [2826509.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Dec;84(24):9040-4 [3321065.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Aug;85(16):5946-50 [3413068.001]
  • [Cites] Mol Neurobiol. 1988 Summer;2(2):133-53 [3077315.001]
  • [Cites] N Engl J Med. 2008 Dec 25;359(26):2814-23 [19109576.001]
  • [Cites] Cancer Metastasis Rev. 2009 Jun;28(1-2):15-33 [19169796.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):265-73 [19262571.001]
  • [Cites] Eur J Endocrinol. 2009 Apr;160(4):695-703 [19176646.001]
  • [Cites] J Cell Sci. 2009 May 1;122(Pt 9):1401-9 [19366726.001]
  • [Cites] Nat Rev Mol Cell Biol. 2009 May;10(5):332-43 [19373241.001]
  • [Cites] J Clin Invest. 2009 Jun;119(6):1420-8 [19487818.001]
  • [Cites] Mol Cell Biol. 2009 Jul;29(13):3722-37 [19414595.001]
  • [Cites] J Cell Biol. 2009 Jun 29;185(7):1159-66 [19564401.001]
  • [Cites] Breast Cancer Res Treat. 2010 May;121(1):65-78 [19593636.001]
  • [Cites] Am J Pathol. 1990 Dec;137(6):1299-304 [1701960.001]
  • (PMID = 20924103.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA134274; United States / NCI NIH HHS / CA / R01 CA124704; United States / NCI NIH HHS / CA / R01-CA124704
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / TWIST1 protein, human; 0 / Tubulin; 0 / Twist Transcription Factor; 42HK56048U / Tyrosine
  • [Other-IDs] NLM/ NIHMS233640; NLM/ PMC3123454
  •  go-up   go-down


18. Briest S, Stearns V: Tamoxifen metabolism and its effect on endocrine treatment of breast cancer. Clin Adv Hematol Oncol; 2009 Mar;7(3):185-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.
  • Tamoxifen is the most common endocrine therapy administered worldwide to women with hormone receptor-positive metastatic breast cancer or as adjuvant therapy for early stages of the disease.
  • Tamoxifen may also be prescribed to women with ductal carcinoma in situ or to decrease the risk of breast cancer in women at high risk of developing the disease.
  • Cytochrome P450 (CYP) 2D6 encodes for a liver enzyme that is responsible for the conversion of tamoxifen into its active metabolite, endoxifen.
  • [MeSH-major] Breast Neoplasms / drug therapy. Cytochrome P-450 CYP2D6 / metabolism. Tamoxifen / metabolism. Tamoxifen / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827855665 for PMID:19398943 [PharmGKB] .
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19398943.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytochrome P-450 CYP2D6 Inhibitors; 094ZI81Y45 / Tamoxifen; EC 1.14.14.1 / Cytochrome P-450 CYP2D6
  • [Number-of-references] 43
  •  go-up   go-down


19. Wiratkapun C, Wibulpolprasert B, Lertsithichai P: Breast cancer in patients initially assigned as BI-RADS category 3. J Med Assoc Thai; 2006 Jun;89(6):834-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer in patients initially assigned as BI-RADS category 3.
  • OBJECTIVES: To determine the Positive Predictive Value (PPV) for malignancy and characteristics of breast cancer found in patients who were initially categorized as having Breast Imaging Reporting and Data System (BI-RADS) 3.
  • MATERIAL AND METHOD: Medical records of patients assigned to BI-RADS 3 from January, 1st to December; 31st 2002 at the Breast diagnostic center, Ramathibodi Hospital who had imaging follow-up for at least 2 years or had biopsy performed were retrospectively reviewed RESULTS: Of 949 patients, 23 were found to have malignancy, i.e., 2.4% PPV.
  • The most common imaging findings of breast cancer were calcifications on mammogram and mass on sonogram.
  • Less than 50% of these were ductal carcinoma in situ or stage I invasive ductal carcinoma.
  • However, longer time to diagnosis and more advanced stage of breast cancer at diagnosis were found Periodically short-interval mammogram and sonogram, at not less than 2 year-intervals, were recommended
  • [MeSH-major] Breast Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Disease Progression. Female. Hospitals, University. Humans. Mammography. Middle Aged. Neoplasm Staging. Population Surveillance. Predictive Value of Tests. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16850685.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


20. Blair SL, Thompson K, Rococco J, Malcarne V, Beitsch PD, Ollila DW: Attaining negative margins in breast-conservation operations: is there a consensus among breast surgeons? J Am Coll Surg; 2009 Nov;209(5):608-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Attaining negative margins in breast-conservation operations: is there a consensus among breast surgeons?
  • BACKGROUND: The purpose of this survey was to ascertain the most common surgical practices for attaining negative (tumor-free) surgical margins in patients desiring breast-conservation treatment for breast cancer to see if a consensus exists for optimal treatment of patients.
  • STUDY DESIGN: We sent a survey to 1,000 surgeons interested in the treatment of breast cancer.
  • RESULTS: Answers showed a large variety in clinical practices among breast surgeons across the country.
  • For example, 57% of surgeons would never reexcise for a positive deep margin, but 53% would always reexcise for a positive anterior margin.
  • Most importantly, there was a large range in answers about acceptable margins with ductal carcinoma in situ and invasive carcinoma.
  • CONCLUSIONS: Results of this survey highlight the wide variety of practice patterns in the US for handling surgical margins in breast-conservation treatment.
  • Consequently, additional study is needed in the modern era of multimodality treatment to examine the minimal amount of surgical treatment necessary, in conjunction with chemotherapy and radiation, to attain adequate local control rates in breast-conservation treatment.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / surgery. Mastectomy, Segmental / standards. Practice Patterns, Physicians' / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / surgery. Female. Frozen Sections. Health Care Surveys. Humans. Intraoperative Period. Lymphatic Metastasis. Male. Middle Aged. Surveys and Questionnaires. United States

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Coll Surg. 2010 Jun;210(6):1012 [20510813.001]
  • [CommentIn] J Am Coll Surg. 2010 Jun;210(6):1015-6 [20510817.001]
  • (PMID = 19854401.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


21. Hambly NM, McNicholas MM, Phelan N, Hargaden GC, O'Doherty A, Flanagan FL: Comparison of digital mammography and screen-film mammography in breast cancer screening: a review in the Irish breast screening program. AJR Am J Roentgenol; 2009 Oct;193(4):1010-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of digital mammography and screen-film mammography in breast cancer screening: a review in the Irish breast screening program.
  • OBJECTIVE: Clinical trials to date into the use of full-field digital mammography (FFDM) for breast cancer screening have shown variable results.
  • The aim of this study was to review the use of FFDM in a population-based breast cancer screening program and to compare the results with screen-film mammography.
  • All films were double read using a 5-point rating scale to indicate the probability of cancer.
  • The recall rate, cancer detection rate, and positive predictive value (PPV) of FFDM were compared with screen-film mammography.
  • RESULTS: The cancer detection rate was significantly higher for FFDM than screen-film mammography (6.3 vs 5.2 per 1,000, respectively; p = 0.01).
  • The cancer detection rate for FFDM was higher than screen-film mammography for initial screening and subsequent screening, for invasive cancer and ductal carcinoma in situ, and across all age groups.
  • The cancer detection rate for cancers presenting as microcalcifications was significantly higher for FFDM than for screen-film mammography (1.9 vs 1.3 per 1,000, p = 0.01).
  • CONCLUSION: FFDM resulted in significantly higher cancer detection and recall rates than screen-film mammography in women 50-64 years old.
  • The results of this study suggest that FFDM can be safely implemented in breast cancer screening programs.
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / radiography. Mammography / utilization. Mass Screening / statistics & numerical data. Radiographic Image Enhancement / methods. Registries. X-Ray Film / utilization


22. Kunju LP, Kleer CG: Significance of flat epithelial atypia on mammotome core needle biopsy: Should it be excised? Hum Pathol; 2007 Jan;38(1):35-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to determine the morphologic types, associations, and significance of flat epithelial atypia (FEA) with or without atypical ductal hyperplasia (ADH) in mammotome core needle biopsies.
  • We evaluated the correlation of FEA in core biopsies with follow-up excision biopsies to predict the likelihood of upgrade to carcinoma.
  • We also investigated the utility of Ki-67 in predicting which lesions were associated with carcinoma in the excisional biopsies.
  • Core biopsies with a diagnosis of atypia were categorized as pure FEA, pure ADH, or both.
  • Excisional biopsies in 48 of 56 patients demonstrated ductal carcinoma in situ and/or invasive carcinoma in 10 patients (21%), lobular carcinoma in situ or atypical lobular hyperplasia in 5 (11%), residual ADH in 11 (23%), and no atypia in 24 patients (50%).
  • Three (21%) of 14 pure FEA upgraded to ductal carcinoma in situ and/or invasive carcinoma on excisional biopsy.
  • The staining for Ki-67 in FEA/ADH was similar regardless of whether they were upgraded to carcinoma or not.
  • Most FEAs have a low-power appearance of a well-circumscribed group of ducts.
  • Chronic inflammation and stromal changes are present in a subset of cases.
  • Flat epithelial atypia shows a risk of upgrade to carcinoma similar to that of ADH and, hence, should be recognized and warrants a follow-up excision.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Biopsy, Needle. Carcinoma, Ductal, Breast / etiology. Carcinoma, Ductal, Breast / surgery. Carcinoma, Intraductal, Noninfiltrating / etiology. Carcinoma, Intraductal, Noninfiltrating / surgery. Carcinoma, Lobular / etiology. Carcinoma, Lobular / surgery. Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Humans. Hyperplasia. Immunohistochemistry. Ki-67 Antigen / analysis. Mammography. Middle Aged. Predictive Value of Tests. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2008 Nov;39(11):1713; author reply 1713-4 [18760823.001]
  • (PMID = 17095049.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08CA090876; United States / NCI NIH HHS / CA / R01CA107469
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


23. Plantade R, Gerard F, Hammou JC: [Management of non malignant papillary lesions diagnosed on percutaneous biopsy]. J Radiol; 2006 Mar;87(3):299-305
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of non malignant papillary lesions diagnosed on percutaneous biopsy].
  • [Transliterated title] Les tumeurs papillaires non malignes du sein: quelle prise en charge après diagnostic percutané?
  • PURPOSE: To assess the reliability of percutaneous breast biopsies in diagnosing and managing non malignant papillary lesions and determine if subsequent excision must be systematic.
  • Retrospective review of 2233 breast biopsies over a 43 months period (September 2001 to March 2005): sonographically guided core biopsies (n = 836), ultrasound (n = 346) or stereotactic (n:1051) guided vacuum biopsies.
  • 86 non malignant papillary tumors were diagnosed (core biopsy:28, US:38 and stereotactic guided vacuum biopsy:20).
  • RESULTS: Surgical resection revealed an underestimation of 5/37 (13.5%): 4/19 with core- and 1/18 with vacuum-assisted biopsy corresponding to 4 low grade ductal carcinoma in situ and a microinvasive ductal carcinoma in situ.
  • Of the 9 non operated papillomas after core biopsy, vacuum biopsy revealed an additional underestimation (low-grade ductal carcinoma in situ).
  • No carcinoma was detected during this follow-up.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / therapy. Papilloma / pathology. Papilloma / therapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Radiol. 2006 Mar;87(3):263-4 [16550109.001]
  • (PMID = 16550114.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


24. Li YJ, Wen G, Yang L: [Inspection on angiogenesis in malignant transformation of breast tumor by ultrasound contrast and quantitative analysis]. Zhonghua Yi Xue Za Zhi; 2009 Mar 10;89(9):587-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inspection on angiogenesis in malignant transformation of breast tumor by ultrasound contrast and quantitative analysis].
  • OBJECTIVE: To study the effects of angiogenesis on tumorigenesis and the progression of breast carcinoma and precancerous lesion.
  • METHODS: Real time ultrasound contrast enhanced microvascular imaging (MVI) and time-intensity curve quantitative analysis were conducted on 30 normal controls, 30 cases with simple hyperplasia, 30 cases with atypical hyperplasia (AH), 20 cases with intraductal carcinoma in situ, and 50 cases with invasive ductal carcinoma, all female.
  • Specimens of breast tissues were obtained and immunohistochemistry was used to detect the expression of CD34, a marker of vascular endothelial cells, and vascular endothelial growth factor (VEGF) and its receptor Flk-1/KDR.
  • RESULTS: With the progression of malignant transformation of breast tissue, the expression levels of VEGF and Flk-1/KDR increased gradually, the framework of the vessels became disordered, the levels of MVD and the perfusion parameters, such as peak intensity (PI), area under the curve (AUC), and wash-out time (WOT), increased.
  • There were not significant differences in the PI, AUC, and WOT levels between the groups of AH and in situ cancer, however, the VEGF and Flk-1/KDR levels of the in situ carcinoma group were significantly higher than those of the AH group (both P<0.05).
  • CONCLUSION: Angiogenesis plays an important role in the development of breast carcinoma.
  • Contrast MVI and the main perfusion parameters reflect the rule of angiogenesis activity changing in different precancerous lesions, and can be used as non-invasive methods to screen high risk population.
  • [MeSH-major] Breast Neoplasms / blood supply. Breast Neoplasms / ultrasonography. Neovascularization, Pathologic / ultrasonography. Ultrasonography, Doppler, Color


25. Dalgin GS, Alexe G, Scanfeld D, Tamayo P, Mesirov JP, Ganesan S, DeLisi C, Bhanot G: Portraits of breast cancer progression. BMC Bioinformatics; 2007;8:291
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Portraits of breast cancer progression.
  • RESULTS: We illustrate the method on a public microarray dataset from 36 breast cancer patients of whom 31 were diagnosed with at least two of three pathological stages of disease (atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC).
  • Our method identifies an optimum set of genes and divides the samples into stable clusters which correlate with clinical classification into Luminal, Basal-like and Her2+ subtypes.
  • Our analysis reveals a hierarchical portrait of breast cancer progression and identifies genes and pathways for each stage, grade and subtype.
  • An intriguing observation is that the disease phenotype is distinguishable in ADH and progresses along distinct pathways for each subtype.
  • The genetic signature for disease heterogeneity across subtypes is greater than the heterogeneity of progression from DCIS to IDC within a subtype, suggesting that the disease subtypes have distinct progression pathways.
  • Our method identifies six disease subtype and one normal clusters.
  • The first split separates the normal samples from the cancer samples.
  • Next, the cancer cluster splits into low grade (pathological grades 1 and 2) and high grade (pathological grades 2 and 3) while the normal cluster is unchanged.
  • The final six disease clusters are mapped into one Luminal A, three Luminal B, one Basal-like and one Her2+.
  • CONCLUSION: We confirm that the cancer phenotype can be identified in early stage because the genes altered in this stage progressively alter further as the disease progresses through DCIS into IDC.
  • We identify six subtypes of disease which have distinct genetic signatures and remain separated in the clustering hierarchy.
  • Our findings suggest that the heterogeneity of disease across subtypes is higher than the heterogeneity of the disease progression within a subtype, indicating that the subtypes are in fact distinct diseases.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. Breast Neoplasms / metabolism. Carcinoma, Ductal / diagnosis. Carcinoma, Ductal / metabolism. Gene Expression Profiling / methods. Neoplasm Proteins / analysis
  • [MeSH-minor] Algorithms. Artificial Intelligence. Diagnosis, Computer-Assisted / methods. Disease Progression. Female. Humans. Oligonucleotide Array Sequence Analysis / methods. Pattern Recognition, Automated / methods. Principal Component Analysis. Reproducibility of Results. Sensitivity and Specificity


26. Suh WW, Hillner BE, Pierce LJ, Hayman JA: Cost-effectiveness of radiation therapy following conservative surgery for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys; 2005 Mar 15;61(4):1054-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness of radiation therapy following conservative surgery for ductal carcinoma in situ of the breast.
  • PURPOSE: To assess the cost-effectiveness of radiation therapy (RT) in patients with ductal carcinoma in situ (DCIS) after breast-conserving surgery (BCS).
  • METHODS AND MATERIALS: A Markov model was constructed for a theoretical cohort of 55-year-old women with DCIS over a life-time horizon.
  • Probability estimates for local noninvasive (N-INV), local invasive (INV), and distant recurrences were obtained from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-17.
  • Utilities for eight nonmetastatic health states were collected from both healthy women and DCIS patients.
  • Direct medical (2002 Medicare fee schedule) and nonmedical costs (time and transportation) of RT were ascertained.
  • Sensitivity analyses revealed the ICER to be affected by baseline probability of a local recurrence, relative efficacy of RT in preventing INV, negative impact of an INV on quality of life, and cost of initial RT.
  • Cost of salvage BCS + RT and source of utilities (healthy women vs. DCIS patients) influenced the ICER albeit to a lesser degree.
  • CONCLUSIONS: Addition of RT following BCS for patients with DCIS should not be withheld because of concerns regarding its cost-effectiveness.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Breast Neoplasms / surgery. Carcinoma in Situ / radiotherapy. Carcinoma in Situ / surgery. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / radiotherapy
  • [MeSH-minor] Cost-Benefit Analysis. Decision Trees. Female. Humans. Markov Chains. Middle Aged. Neoplasm Recurrence, Local / economics. Quality-Adjusted Life Years. Radiotherapy / economics. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15752884.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


27. Sebag P, Tourasse C, Rouyer N, Lebas P, Dénier JF, Michenet P: [Value of vacuum assisted biopsies under sonography guidance: results from a multicentric study of 650 lesions]. J Radiol; 2006 Jan;87(1):29-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Place des macrobiopsies mammaires assistées par le vide sous guidage échographique: étude multi-centrique de 650 lésions.
  • Lesions were categorized, using the classification from Stavros, between "probably benign", "indeterminate", "probably malignant" and "malignant" Histology was validated only after review of the clinical and radiological data, as well as surgical data when available.
  • RESULTS: We have identified 471 benign lesions and 179 malignant lesions.
  • Three cancers were diagnosed in the cases of "probably benign lesions" and in the cases of "probably malignant lesions" 18 (27%) were inflammatory disorders.
  • In 5 cases vacuum biopsy underestimated the pathology with regard to surgery: 2 cases of atypical duct hyperplasia (HCA) were in situ ductal carcinoma (DCIS) at surgery and 3 cases of DCIS were infiltrative ductal carcinoma (DCI) at surgery.
  • With this technique we have avoided surgery for 71% of all women who presented an "indeterminate" or "probably malignant" condition.
  • Specificity is excellent with no cancer detected so far among the patients with benign findings, under follow-up.
  • CONCLUSION: Ultrasound guided Vacuum assisted biopsy is a fairly recent minimally invasive technique, with short learning curve.
  • [MeSH-major] Biopsy, Needle / methods. Breast / pathology. Ultrasonography, Interventional. Ultrasonography, Mammary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Fibroadenoma / pathology. Follow-Up Studies. Humans. Hyperplasia. Middle Aged. Minimally Invasive Surgical Procedures. Papilloma / pathology. Phyllodes Tumor / pathology. Retrospective Studies. Sensitivity and Specificity. Vacuum

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16415777.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] France
  •  go-up   go-down


28. Schreer I, Lüttges J: Precursor lesions of invasive breast cancer. Eur J Radiol; 2005 Apr;54(1):62-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor lesions of invasive breast cancer.
  • The increasing application of mammography, mainly in screening programs for the early detection of breast cancer, and the high technical standard of imaging has resulted in the detection of clinically occult breast tumors.
  • Considering that only diagnosis at an early stage will be able to change the prognosis of breast cancer, this diagnostic challenge appears to be the most exciting field in both breast imaging and breast pathology.
  • In imaging, the morphologic appearance of precursor lesions is usually neither typical nor pathognomonic.
  • Recent molecular studies have demonstrated various genetic alterations in the ductal epithelium, with the earliest onset in atypical ductal hyperplasia.
  • The recent WHO classification, which is based on molecular data and histopathological features, attempts to define in particular the precursor lesions and low grade intraductal carcinomas.
  • [MeSH-major] Breast Neoplasms / radiography. Mammography. Precancerous Conditions / radiography
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15797294.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 12
  •  go-up   go-down


29. Weinreb I, Tabanda-Lichauco R, Van der Kwast T, Perez-Ordoñez B: Low-grade intraductal carcinoma of salivary gland: report of 3 cases with marked apocrine differentiation. Am J Surg Pathol; 2006 Aug;30(8):1014-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade intraductal carcinoma of salivary gland: report of 3 cases with marked apocrine differentiation.
  • Low-grade intraductal carcinomas (LG-IDCs) of salivary gland are rare neoplasms that resemble atypical ductal hyperplasia or LG-IDCs of the breast.
  • They have been referred to as "low-grade salivary duct carcinomas" or "low-grade cribriform cystadenocarcinomas."
  • Herein, we describe 3 additional cases of LG-IDCs, 2 were pure intraductal carcinomas, although 1 demonstrated increasing cytologic atypia and progression to an invasive adenosquamous carcinoma.
  • The latter had been present for 7 years before demonstrating clinical and pathologic progression to a widely invasive malignancy.
  • The intraductal component in all cases exhibited a remarkable degree of apocrine differentiation.
  • The intraductal neoplastic cells were surrounded by myoepithelial cells positive for CK14, actins, calponin, high molecular weight keratin, and p63.
  • Extensive apocrine differentiation, expression of ARs, CK7, and CK19, and progression to a widely invasive carcinoma after a long clinical latency have not been reported in LG-IDCs previously.
  • These tumors share some histopathologic features with salivary duct carcinoma including apocrine differentiation, and expression of ARs and BRST-2.
  • The terms "low-grade salivary duct carcinomas" and "low-grade cribriform cystadenocarcinomas" should be abandoned in favor of LG-IDC of salivary gland, which better reflects their predominantly noninvasive, intraductal nature.
  • [MeSH-major] Apocrine Glands / pathology. Carcinoma, Ductal / metabolism. Carcinoma, Ductal / pathology. Salivary Gland Neoplasms / metabolism. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / pathology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasms, Multiple Primary / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861974.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


30. Krajewska M, Kim H, Shin E, Kennedy S, Duffy MJ, Wong YF, Marr D, Mikolajczyk J, Shabaik A, Meinhold-Heerlein I, Huang X, Banares S, Hedayat H, Reed JC, Krajewski S: Tumor-associated alterations in caspase-14 expression in epithelial malignancies. Clin Cancer Res; 2005 Aug 1;11(15):5462-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Tumor-associated alterations in caspase-14 expression were observed for cervical, ovarian, breast, gastric, and colon cancers.
  • Decreases in caspase-14 immunopositivity correlated with the histologic progression of cervical cancer (P < 0.0001, ANOVA).
  • Lower caspase-14 expression was associated with advanced clinical stage in ovarian cancer (P = 0.04, ANOVA) and with shorter overall survival among ovarian cancer patients with serous tumors (n = 62) in both univariate (P = 0.005) and multivariate (P = 0.03) analysis.
  • In contrast to cervical, ovarian, and colon cancers, caspase-14 expression was increased in ductal carcinoma in situ and invasive cancers compared with normal mammary epithelium (P = 0.001, t test).
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Caspase 14. Cell Differentiation. Cell Line, Tumor. Colonic Neoplasms / pathology. Disease Progression. Female. Humans. Immunoblotting. Immunohistochemistry. Microsatellite Repeats. Oligonucleotide Array Sequence Analysis. Ovarian Neoplasms / pathology. Proportional Hazards Models. Stomach Neoplasms / pathology. Time Factors. Uterine Cervical Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061862.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA098818-01; United States / NCI NIH HHS / CA / CA69381
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.22.- / CASP14 protein, human; EC 3.4.22.- / Caspase 14; EC 3.4.22.- / Caspases
  •  go-up   go-down


31. Ikeda T, Jinno H, Shirane M: Chemosensitivity-related genes of breast cancer detected by DNA microarray. Anticancer Res; 2007 Jul-Aug;27(4C):2649-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemosensitivity-related genes of breast cancer detected by DNA microarray.
  • BACKGROUND: The feasibility of a preoperative docetaxel/5'-deoxy-5-fluorouridine (5'-DFUR) regimen for breast cancer patients was examined and the genes related to the response to it was investigated.
  • PATIENTS AND METHODS: Women with advanced breast cancer were treated with docetaxel (60 mg/m2, day 1) and 5'-DFUR (800 mg/day, on days 1-14) q3 weeks by 4 cycles.
  • RESULTS: The docetaxel/5'-DFUR regimen showed a 86% clinical response rate including 42% complete response, one pathological complete response and one ductal carcinoma in situ component.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695428.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Taxoids; 039LU44I5M / Floxuridine; 15H5577CQD / docetaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


32. Ellsworth RE, Ellsworth DL, Love B, Patney HL, Hoffman LR, Kane J, Hooke JA, Shriver CD: Correlation of levels and patterns of genomic instability with histological grading of DCIS. Ann Surg Oncol; 2007 Nov;14(11):3070-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of levels and patterns of genomic instability with histological grading of DCIS.
  • BACKGROUND: Histological grading of ductal carcinoma-in-situ (DCIS) lesions separates DCIS into three subgroups (well-, moderately, or poorly differentiated).
  • It is unclear, however, whether breast disease progresses along a histological continuum or whether each grade represents a separate disease.
  • In this study, levels and patterns of allelic imbalance (AI) were examined in DCIS lesions to develop molecular models that can distinguish pathological classifications of DCIS.
  • METHODS: Laser microdissected DNA samples were collected from DCIS lesions characterized by a single pathologist including well- (n = 18), moderately (n = 35), and poorly differentiated (n = 47) lesions.
  • A panel of 52 microsatellite markers representing 26 chromosomal regions commonly altered in breast cancer was used to assess patterns of AI.
  • Levels of AI were not significantly different between well- and moderately differentiated grades of disease but were significantly higher (P < .0001) in poorly differentiated compared with well- or moderately differentiated disease.
  • No statistically significant differences in patterns of AI were detected between well- and moderately differentiated disease; however, AI occurred significantly more frequently (P < .05) in high-grade lesions at chromosomes 6q25-q27, 8q24, 9p21, 13q14, and 17p13.1, and significantly more frequently in low-grade lesions at chromosome 16q22.3-q24.3.
  • CONCLUSIONS: The inability to discriminate DCIS at the genetic level suggests that grades 1 and 2 DCIS may represent a single, non-high-grade form of DCIS, whereas poorly differentiated DCIS seems to be a genetically more advanced disease that may represent a discrete disease entity, characterized by a unique spectrum of genetic alterations.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Carcinoma, Intraductal, Noninfiltrating / genetics. Chromosome Aberrations. Chromosomes, Human / ultrastructure. Genomic Instability
  • [MeSH-minor] Allelic Imbalance. Chromosome Mapping. DNA / genetics. DNA, Neoplasm / genetics. DNA, Neoplasm / metabolism. Female. Humans. Middle Aged. Prevalence. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2007 Nov;14(11):3033-4 [17705090.001]
  • (PMID = 17549568.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 9007-49-2 / DNA
  •  go-up   go-down


33. Lau EM, Yee BJ, Grunstein RR, Celermajer DS: Patent foramen ovale and obstructive sleep apnea: a new association? Sleep Med Rev; 2010 Dec;14(6):391-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PFO has received much clinical interest because it has been implicated in disease states such as stroke, migraine and decompression illness.
  • Furthermore, minimally invasive percutaneous techniques are now available for closure of PFO.

  • Genetic Alliance. consumer health - Sleep Apnea.
  • Genetic Alliance. consumer health - Patent Foramen Ovale.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright © 2010. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20451427.001).
  • [ISSN] 1532-2955
  • [Journal-full-title] Sleep medicine reviews
  • [ISO-abbreviation] Sleep Med Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


34. Buchholz TA, Haffty BG, Harris JR: Should all patients undergoing breast conserving therapy for DCIS receive radiation therapy? Yes. Radiation therapy, an important component of breast conserving treatment for patients with ductal carcinoma in situ of the breast. J Surg Oncol; 2007 Jun 15;95(8):610-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should all patients undergoing breast conserving therapy for DCIS receive radiation therapy? Yes. Radiation therapy, an important component of breast conserving treatment for patients with ductal carcinoma in situ of the breast.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Breast Neoplasms / surgery. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Carcinoma, Intraductal, Noninfiltrating / surgery. Mastectomy, Segmental
  • [MeSH-minor] Combined Modality Therapy. Evidence-Based Medicine. Female. Humans. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Surg Oncol. 2007 Jun 15;95(8):605-9 [17192948.001]
  • (PMID = 17221862.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


36. Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, Yamamoto Y, Iwase T: Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer; 2010 Apr;17(2):118-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
  • BACKGROUND: Triple negative (TN) breast cancer is defined as a subtype that is negative for estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2).
  • To clarify the characteristics of TN breast cancer, surveillance data of the Registration Committee of the Japanese Breast Cancer Society were analyzed.
  • Of these, the most prevalent (53.8%) was a hormone-responsive subtype with ER positive/PgR positive/HER2 negative, followed by TN subtype (15.5%).
  • RESULTS: The proportion of postmenopausal patients was relatively high in the TN subtype.
  • This cancer was diagnosed at a slightly advanced stage and with more cases positive for lymph node metastases than other subtypes.
  • Morphologically, the TN subtype was more frequently classified as solid-tubular carcinoma.
  • Mucinous, tubular, or secretary carcinomas were frequently found in the hormone receptor positive/HER2 negative subtype, while squamous cell carcinoma, spindle cell carcinoma, and metaplastic carcinoma with bone/cartilage metaplasia were very frequently found in the TN group.
  • Apocrine carcinoma was also found very frequently in the TN group.
  • CONCLUSIONS: Although TN types are similar to basal-like breast tumor, as determined by gene profiling, their diagnosis needs verification by determination of the level of epidermal growth factor receptor or cytokeratin 5/6 expression.
  • [MeSH-major] Breast Neoplasms / pathology. Receptor, Epidermal Growth Factor / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Scirrhous / metabolism. Adenocarcinoma, Scirrhous / pathology. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Female. Humans. Japan. Middle Aged. Prognosis. Receptor, ErbB-2 / metabolism. Registries. Societies, Medical / statistics & numerical data. Young Adult


37. Camp ER, McAuliffe PF, Gilroy JS, Morris CG, Lind DS, Mendenhall NP, Copeland EM 3rd: Minimizing local recurrence after breast conserving therapy using intraoperative shaved margins to determine pathologic tumor clearance. J Am Coll Surg; 2005 Dec;201(6):855-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimizing local recurrence after breast conserving therapy using intraoperative shaved margins to determine pathologic tumor clearance.
  • BACKGROUND: This study analyzed survival, locoregional recurrence, and reexcision rates after breast conserving therapy, based on the margin analysis technique used at the University of Florida, which incorporates frozen section analysis of shaved breast tissue from the lumpectomy cavity.
  • RESULTS: Breast conserving therapy was performed for 220 (83%) patients with early breast cancer (T1 and T2 tumors) and 47 (17%) with ductal carcinoma in situ.
  • With a median followup of 5.6 years, the crude locoregional recurrence rates for patients who had margins analyzed intraoperatively by frozen section analysis or margins analyzed by permanent analysis were 1.9% (3 of 157) and 3.1% (2 of 63), respectively, for early breast cancer and 15.6% (5 of 32) and 6.6% (1 of 15) for ductal carcinoma in situ (p=NS).
  • Survival rates were 97% and 78%, at 5 and 10 years, respectively, for the early breast cancer patients, and 98% and 98%, respectively, for ductal carcinoma in situ patients.
  • CONCLUSIONS: Regardless of the technique used for margin analysis, breast conserving therapy led to low locoregional recurrence relative to national figures, pointing to the importance of the technique of radiation therapy at our institution.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / surgery. Carcinoma in Situ / surgery. Carcinoma, Ductal / surgery. Mastectomy, Segmental. Neoplasm Recurrence, Local / prevention & control


38. Moore KH, Sweeney KJ, Wilson ME, Goldberg JI, Buchanan CL, Tan LK, Liberman L, Turner RR, Lagios MD, Cody Iii HS, Giuliano AE, Silverstein MJ, Van Zee KJ: Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit. Ann Surg Oncol; 2007 Oct;14(10):2911-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit.
  • BACKGROUND: A positive sentinel lymph node (SLN) has been reported in 6% to 13% of patients with ductal carcinoma in situ (DCIS).
  • Although it is well established that nodal status for invasive disease is prognostically important, the clinical relevance of a positive SLN in patients with DCIS remains undetermined.
  • METHODS: SLN biopsy was performed on 470 high-risk patients with DCIS (22% of all patients with DCIS) at 3 institutions.
  • At 2 of the 3 institutions, data were also collected on DCIS patients who had negative findings on SLN biopsy.
  • RESULTS: Extensive disease requiring mastectomy (p = 0.02) and the presence of necrosis (p = 0.04) were associated with an increased risk of nodal positivity.
  • Nine of 43 (21%) high-risk DCIS patients with a positive SLN and 9/470 (2%) of all high-risk DCIS patients were upstaged to AJCC stage I or II as a result of the SLN biopsy.
  • This patient had immunohistochemistry detected isolated tumor cells in her SLN (N0(i+)), and upon pathologic review, was found to have high-grade DCIS with microinvasion.
  • CONCLUSION: SLN biopsy for high-risk DCIS patients is a mean of detecting those who may have unrecognized invasive disease and therefore are at risk for distant disease.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma, Intraductal, Noninfiltrating / surgery. Lymph Node Excision. Lymphatic Metastasis / pathology. Mastectomy. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Axilla. Breast / pathology. Female. Follow-Up Studies. Humans. Liver / pathology. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Middle Aged. Necrosis. Neoplasm Invasiveness / pathology. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17597346.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


39. Dotto J, Kluk M, Geramizadeh B, Tavassoli FA: Frequency of clinically occult intraepithelial and invasive neoplasia in reduction mammoplasty specimens: a study of 516 cases. Int J Surg Pathol; 2008 Jan;16(1):25-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of clinically occult intraepithelial and invasive neoplasia in reduction mammoplasty specimens: a study of 516 cases.
  • Reduction mammoplasty is a frequently performed procedure for the treatment of macromastia and for the achievement of symmetry in breast cancer patients following lumpectomy.
  • Among these, 92 (18%) low-risk ductal intraepithelial neoplasia/intraductal hyperplasia, 28 (5%) ductal intraepithelial neoplasia 1 (1 low-grade ductal carcinoma in situ, 11 atypical intraductal hyperplasia, and 16 flat type), 17 (3%) lobular intraepithelial neoplasia, and 1 (0.2%) tubular carcinoma were identified.
  • These data confirm the low frequency of clinically occult malignancies identified in reduction mammoplasty specimens and provide substantial information about the frequency of a variety of intraepithelial proliferations.
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / pathology. Mammaplasty

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Reconstruction.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18203780.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Newton HB, Padilla W, Burkart J, Pearl DK: Neurological manifestations of decompression illness in recreational divers - the Cozumel experience. Undersea Hyperb Med; 2007 Sep-Oct;34(5):349-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurological manifestations of decompression illness in recreational divers - the Cozumel experience.
  • Neurological signs and symptoms are common in recreational divers with decompression illness (DCI).
  • The spectrum of neurological manifestations, temporal profile, and laboratory findings are described in a large series of 200 consecutive recreational divers treated for DCI.
  • The Hyperbaric Medicine Unit charts of 200 recreational divers treated for DCI were reviewed and analyzed.
  • One hundred seventy-seven of 200 divers (88.5%) had at least one symptom of neurological DCI at presentation.
  • Neurological manifestations are common in recreational divers treated for DCI.
  • Neurological DCI and paresthesias are more likely to occur in younger and less experienced divers.
  • [MeSH-major] Decompression Sickness / complications. Diving / adverse effects. Nervous System Diseases / etiology

  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019086.001).
  • [ISSN] 1066-2936
  • [Journal-full-title] Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc
  • [ISO-abbreviation] Undersea Hyperb Med
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16058
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


41. King C, Guo N, Frampton GM, Gerry NP, Lenburg ME, Rosenberg CL: Reliability and reproducibility of gene expression measurements using amplified RNA from laser-microdissected primary breast tissue with oligonucleotide arrays. J Mol Diagn; 2005 Feb;7(1):57-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reliability and reproducibility of gene expression measurements using amplified RNA from laser-microdissected primary breast tissue with oligonucleotide arrays.
  • We performed eight U133A Affymetrix GeneChip oligonucleotide array hybridizations using RNA isolated from a single normal human breast specimen: two standard and six small samples prepared using independent microdissections, RNA isolations, and amplifications.
  • We then performed six array hybridizations using RNA obtained similarly from paired normal epithelium and ductal carcinoma in situ from three independent breast specimens.
  • In contrast, in the three normal cancer pairs, the differences in gene expression were large among the normal samples, the ductal carcinoma in situ samples, and between normal and ductal carcinoma in situ within each pair.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Jun 29;19(28):3220-4 [10918578.001]
  • [Cites] Biotechniques. 2000 Sep;29(3):530-6 [10997267.001]
  • [Cites] Nucleic Acids Res. 2001 Mar 1;29(5):E29 [11222780.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2005-10 [11395378.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6196-204 [11593428.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):801-13 [11891179.001]
  • [Cites] BMC Genomics. 2003;4(1):4 [12594857.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 24;300(4):915-20 [12559960.001]
  • [Cites] Biotechniques. 2003 Mar;34(3):546-50, 552-4, 556 [12661160.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9 [12714683.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Mar;87(5):1663-7 [1689846.001]
  • [Cites] Science. 1996 Nov 8;274(5289):998-1001 [8875945.001]
  • [Cites] Nat Med. 1999 Jan;5(1):117-22 [9883850.001]
  • [Cites] J Mol Diagn. 2003 Feb;5(1):9-14 [12552074.001]
  • (PMID = 15681475.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA081078; United States / NCI NIH HHS / CA / CA081078
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC1867505
  •  go-up   go-down


42. Wong JS: Is radiotherapy boost needed in young patients with ductal carcinoma-in-situ? Lancet Oncol; 2006 Aug;7(8):615-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is radiotherapy boost needed in young patients with ductal carcinoma-in-situ?
  • [MeSH-major] Carcinoma in Situ / radiotherapy. Carcinoma, Ductal, Breast / radiotherapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Lancet Oncol. 2006 Aug;7(8):652-6 [16887482.001]
  • (PMID = 16887475.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


43. Huzarski T, Lener M, Domagała W, Gronwald J, Byrski T, Kurzawski G, Suchy J, Chosia M, Woyton J, Ucinski M, Narod SA, Lubiński J: The 3020insC allele of NOD2 predisposes to early-onset breast cancer. Breast Cancer Res Treat; 2005 Jan;89(1):91-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The 3020insC allele of NOD2 predisposes to early-onset breast cancer.
  • The NOD2 gene has been associated with susceptibility to Crohn's disease, and more recently with carcinoma of the colon as well.
  • The range of cancer types associated with NOD2 has not been well studied.
  • The 3020insC allele results in a truncated NOD2 protein and is present in approximately 7% of the population.
  • We studied a possible association between the 3020insC allele of the NOD2 gene and breast cancer using 462 cases and 1910 controls from Poland.
  • Patients were diagnosed with invasive breast cancer at are of two Szczecin regional hospitals between 2002 and 2004.
  • Pathology specimens were reviewed for histological subtype and for the presence of ductal carcinoma in situ (DCIS).
  • Overall there was no association between breast cancer and NOD2 (OR = 1.1; p = 0.76), but significant associations were observed between the presence of the allele and early-onset breast cancer (OR = 1.9; p = 0.01) and between the allele and ductal breast cancer with an in situ component (OR = 2.2; p = 0.006).
  • [MeSH-major] Alleles. Breast Neoplasms / epidemiology. Breast Neoplasms / genetics. Carcinoma, Intraductal, Noninfiltrating / epidemiology. Carcinoma, Intraductal, Noninfiltrating / genetics. Genetic Predisposition to Disease / epidemiology. Genetic Predisposition to Disease / genetics. Intracellular Signaling Peptides and Proteins

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15666202.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / NOD2 protein, human; 0 / Nod2 Signaling Adaptor Protein
  •  go-up   go-down


44. Smith GL, Smith BD, Haffty BG: Rationalization and regionalization of treatment for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys; 2006 Aug 1;65(5):1397-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rationalization and regionalization of treatment for ductal carcinoma in situ of the breast.
  • PURPOSE: In ductal carcinoma in situ (DCIS) of the breast, conservative surgery plus radiotherapy (CS+RT) decreases risk of recurrence compared with CS alone.
  • We evaluated national patterns of DCIS treatment from 1996 to 2001 by patient risk profile.
  • METHODS AND MATERIALS: In a retrospective cohort of DCIS patients from the Surveillance, Epidemiology, and End Results data, patients were risk stratified on the basis of age at diagnosis, tumor grade, tumor size, and comedo histology.
  • Patients were followed for the development of ipsilateral invasive or in situ event.
  • CONCLUSION: Patient risk profiles rationally affect treatment choice in DCIS patients, and the vast majority of high-risk patients do not receive CS alone.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Breast Neoplasms / surgery. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Carcinoma, Intraductal, Noninfiltrating / surgery. Practice Patterns, Physicians' / trends
  • [MeSH-minor] Combined Modality Therapy / methods. Combined Modality Therapy / trends. Female. Humans. Logistic Models. Mastectomy, Segmental / trends. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Neoplasms, Second Primary / prevention & control. Risk Assessment. United States

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750316.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM07205
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


45. Tejada JG, Taylor RA, Ugurel MS, Hayakawa M, Lee SK, Chaloupka JC: Safety and feasibility of intra-arterial nicardipine for the treatment of subarachnoid hemorrhage-associated vasospasm: initial clinical experience with high-dose infusions. AJNR Am J Neuroradiol; 2007 May;28(5):844-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and feasibility of intra-arterial nicardipine for the treatment of subarachnoid hemorrhage-associated vasospasm: initial clinical experience with high-dose infusions.
  • BACKGROUND AND PURPOSE: Delayed cerebral ischemia from vasospasm is a major complication after aneurysmal subarachnoid hemorrhage (SAH), but complications and/or low efficacy are associated with current therapy.
  • We report our initial experience with intra-arterial use of a calcium channel blocker, nicardipine.
  • MATERIALS AND METHODS: A retrospective review of a consecutive series of patients with clinical and angiographic vasospasm treated with intra-arterial nicardipine was performed.
  • CONCLUSION: In this small series, high-dose intra-arterial nicardipine infusion to treat SAH-associated vasospasm seems to be safe and effective.
  • [MeSH-minor] Adult. Aged. Cerebral Angiography. Feasibility Studies. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Postoperative Complications / drug therapy. Postoperative Complications / etiology. Postoperative Complications / radiography. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17494654.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vasodilator Agents; CZ5312222S / Nicardipine
  •  go-up   go-down


46. Hruska CB, Boughey JC, Phillips SW, Rhodes DJ, Wahner-Roedler DL, Whaley DH, Degnim AC, O'Connor MK: Scientific Impact Recognition Award: Molecular breast imaging: a review of the Mayo Clinic experience. Am J Surg; 2008 Oct;196(4):470-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scientific Impact Recognition Award: Molecular breast imaging: a review of the Mayo Clinic experience.
  • BACKGROUND: Molecular breast imaging (MBI) depicts functional uptake of targeted radiotracers in the breast using dedicated gamma cameras.
  • METHODS: MBI studies were performed under several institutional protocols evaluating the use of MBI in screening and diagnosis.
  • RESULTS: By using a single-head system, sensitivity for breast cancer detection was 85% (57 of 67) overall and 29% for tumors 5 mm or less in diameter.
  • In 650 high-risk patients undergoing breast cancer screening, MBI detected 7 cancers, 5 of which were missed on mammography.
  • In 24 of 149 (16%) breast cancer patients MBI detected additional disease not seen on mammography.
  • The sensitivity of MBI was 88% (83 of 94) for invasive ductal carcinoma, 79% (23 of 29) for invasive lobular carcinoma, and 89% (25 of 28) for ductal carcinoma in situ.
  • CONCLUSIONS: MBI can detect invasive ductal carcinoma, ductal carcinoma in situ, and invasive lobular carcinoma.
  • It has a promising role in evaluating the extent of disease and multifocal disease in the breast for surgical treatment planning.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiol Clin North Am. 2001 Sep;39(5):1053-68 [11587058.001]
  • [Cites] Cancer. 2001 May 1;91(9):1724-31 [11335897.001]
  • [Cites] Ann Intern Med. 2002 Sep 3;137(5 Part 1):347-60 [12204020.001]
  • [Cites] Radiology. 2002 Oct;225(1):165-75 [12355001.001]
  • [Cites] Ann Intern Med. 2003 Feb 4;138(3):168-75 [12558355.001]
  • [Cites] J Nucl Med. 2003 Apr;44(4):602-9 [12679406.001]
  • [Cites] AJR Am J Roentgenol. 2003 Jun;180(6):1675-9 [12760942.001]
  • [Cites] JAMA. 1995 Jan 11;273(2):149-54 [7799496.001]
  • [Cites] Eur J Nucl Med. 1997 Feb;24(2):150-9 [9021112.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1677-83 [9586878.001]
  • [Cites] Mayo Clin Proc. 2005 Jan;80(1):24-30 [15667025.001]
  • [Cites] Womens Health Issues. 2005 Mar-Apr;15(2):55-63 [15767195.001]
  • [Cites] Nucl Med Commun. 2005 May;26(5):441-5 [15838427.001]
  • [Cites] Breast J. 2007 Jan-Feb;13(1):3-11 [17214787.001]
  • [Cites] Breast. 2007 Jun;16(3):262-70 [17291755.001]
  • [Cites] Int J Oncol. 2007 Aug;31(2):369-77 [17611694.001]
  • [Cites] Breast. 2007 Dec;16 Suppl 2:S34-44 [17959382.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Phys Med Biol. 2000 Nov;45(11):3481-8 [11098918.001]
  • [Cites] J Nucl Med. 2000 Dec;41(12):1973-9 [11138681.001]
  • [Cites] Radiology. 2002 Jan;222(1):149-55 [11799940.001]
  • (PMID = 18723155.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA110162-01; United States / NCI NIH HHS / CA / R21 CA110162-02; United States / NCI NIH HHS / CA / R21 CA110162-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  • [Other-IDs] NLM/ NIHMS71781; NLM/ PMC2603338
  •  go-up   go-down


47. Tuttle TM, Shamliyan T, Virnig BA, Kane RL: The impact of sentinel lymph node biopsy and magnetic resonance imaging on important outcomes among patients with ductal carcinoma in situ. J Natl Cancer Inst Monogr; 2010;2010(41):117-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of sentinel lymph node biopsy and magnetic resonance imaging on important outcomes among patients with ductal carcinoma in situ.
  • The objective of this systematic review was to determine the impact of sentinel lymph node (SLN) biopsy and breast magnetic resonance imaging (MRI) on important outcomes for patients with ductal carcinoma in situ.
  • So, we determined the incidence of SLN metastases among patients with ductal carcinoma in situ.
  • Using American Joint Committee on Cancer criteria, the incidence of pN1 and pN1(mic) SLN metastases were 0.9% and 1.5%, respectively.
  • We identified one study that directly evaluated important outcomes after breast MRI.
  • In this study, the use of MRI did not affect local recurrence rates after breast-conserving surgery and radiation.
  • Although MRI may identify occult multicentric or contralateral breast cancer in some patients, it may also lead to unnecessary biopsies and overtreatment.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / secondary. Lymphatic Metastasis / diagnosis. Magnetic Resonance Imaging. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Axilla. Carcinoma, Ductal, Breast / secondary. Female. Humans. Incidence. Mastectomy, Segmental. Neoplasm Recurrence, Local / epidemiology. Neoplasms, Multiple Primary / diagnosis. Retrospective Studies. Sensitivity and Specificity. Treatment Outcome. Unnecessary Procedures

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20956814.001).
  • [ISSN] 1745-6614
  • [Journal-full-title] Journal of the National Cancer Institute. Monographs
  • [ISO-abbreviation] J. Natl. Cancer Inst. Monographs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


48. Feigin VL, Anderson N, Rinkel GJ, Algra A, van Gijn J, Bennett DA: Corticosteroids for aneurysmal subarachnoid haemorrhage and primary intracerebral haemorrhage. Cochrane Database Syst Rev; 2005;(3):CD004583
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (2) to determine whether corticosteroid therapy reduces the frequency of delayed cerebral ischaemia (DCI) in patients with SAH;.
  • (2) development of delayed cerebral ischaemia (as defined by the trialists) in patients with SAH; and (3) adverse effects of the treatment during the scheduled treatment or follow-up period (secondary outcomes).
  • AUTHORS' CONCLUSIONS: Overall, there is no evidence of a beneficial or adverse effect of corticosteroids in patients with either SAH or PICH.
  • [MeSH-major] Adrenal Cortex Hormones / therapeutic use. Cerebral Hemorrhage / drug therapy. Intracranial Aneurysm / complications

  • MedlinePlus Health Information. consumer health - Brain Aneurysm.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. FLUDROCORTISONE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16034939.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 7S5I7G3JQL / Dexamethasone; U0476M545B / Fludrocortisone; WI4X0X7BPJ / Hydrocortisone; X4W7ZR7023 / Methylprednisolone
  • [Number-of-references] 39
  •  go-up   go-down


49. Jim HS, Donovan KA, Small BJ, Andrykowski MA, Munster PN, Jacobsen PB: Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer; 2009 Apr 15;115(8):1776-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cognitive functioning in breast cancer survivors: a controlled comparison.
  • BACKGROUND: The current study was performed to determine whether neuropsychologic functioning differs in breast cancer survivors 6 months after the completion of adjuvant treatment compared with women without cancer.
  • METHODS: Participants were 187 women who were diagnosed with ductal carcinoma in situ or stage I or stage II breast cancer and 187 age-matched and geographically matched women without cancer.
  • Of the survivors, 97 had been treated after surgery with chemotherapy only or chemotherapy plus radiotherapy and 90 had been treated after surgery with radiotherapy only (grading determined according to the American Joint Committee on Cancer grading system).
  • CONCLUSIONS: Data from the current study suggest that cognitive deficits are subtle and likely the result of the general effects of cancer diagnosis and treatment rather than systemic treatment.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2695-701 [10894868.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):640-50 [10091737.001]
  • [Cites] J Natl Cancer Inst. 2003 Feb 5;95(3):190-7 [12569140.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4175-83 [14615445.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):405-12 [14623538.001]
  • [Cites] J Int Neuropsychol Soc. 2003 Nov;9(7):967-82 [14738279.001]
  • [Cites] Psychooncology. 2004 Jan;13(1):61-6 [14745746.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2292-9 [15160331.001]
  • [Cites] Cancer. 1992 Nov 1;70(9):2288-97 [1394058.001]
  • [Cites] J Clin Exp Neuropsychol. 1994 Feb;16(1):93-104 [8150893.001]
  • [Cites] J Natl Cancer Inst. 1998 Feb 4;90(3):210-8 [9462678.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1689-96 [9586880.001]
  • [Cites] Qual Life Res. 1998 May;7(4):301-10 [9610214.001]
  • [Cites] J Psychosom Res. 1999 May;46(5):437-43 [10404478.001]
  • [Cites] Breast. 2005 Apr;14(2):142-50 [15767184.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8025-32 [16258100.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2499-507 [16247788.001]
  • [Cites] Cancer. 2005 Dec 1;104(11 Suppl):2565-76 [16258929.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):828-34 [16523200.001]
  • [Cites] Patient Educ Couns. 2007 Apr;66(1):108-18 [17320337.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jul;103(3):303-11 [17009108.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1387-97 [12196364.001]
  • (PMID = 19224550.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA082822-08S1; United States / NCI NIH HHS / CA / R01 CA082822; United States / NCI NIH HHS / CA / R01 CA082822-08S1; United States / NCI NIH HHS / CA / R01 CA82822
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS89262; NLM/ PMC2668740
  •  go-up   go-down


50. Logullo AF, Nonogaki S, Pasini FS, Osório CA, Soares FA, Brentani MM: Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression. Oncol Rep; 2010 Feb;23(2):313-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression.
  • Epithelial to mesenchymal transition (EMT) is a process implicated in cancer progression in which the underlying cellular changes have been identified mainly using in vitro models.
  • We determined the expression of some putative EMT biomarkers including E-cadherin, beta-catenin, zinc finger factor Snail (Snail), transforming growth factor beta1 (TGFbeta1), TGFbeta type II receptor (TBRII) and the HGF receptor (c-met) and their possible correlation to progression and overall survival in a series of breast ductal carcinoma in situ (DCIS) and invasive ductal carcinomas (IDC).
  • Biomarkers were immunohistochemically determined in 55 IDC specimens from which 21 had lymph node metastases and in 95 DCIS specimens, 46 of these cases associated to invasive carcinoma, in a tissue microarray (TMA).
  • A significant increase of c-met and TGFbeta1 positivity along DCIS to IDC progression was noted but only TGFbeta1 positivity was associated with presence of lymph node metastases and advanced stages in IDC.
  • The evaluation of the other EMT markers in DCIS did not show differences in positivity rate as compared to invasive carcinomas.
  • DCIS either pure or associated to IDC showed similar expression of the analyzed biomarkers.
  • All the carcinomas exhibited positive expression of TBRII.
  • Associations between the markers, determined by Spearman's correlation coefficient, showed a significant association between TGFbeta1 and respectively E-cadherin, beta-catenin and c-met in DCIS cases, but in invasive carcinomas only cadherin and catenin were positively correlated.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Cell Transformation, Neoplastic / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Epithelium / pathology. Female. Humans. Mesoderm / pathology. Middle Aged. Survival Analysis. Tissue Array Analysis


51. Vann RD, Denoble PJ, Howle LE, Weber PW, Freiberger JJ, Pieper CF: Resolution and severity in decompression illness. Aviat Space Environ Med; 2009 May;80(5):466-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resolution and severity in decompression illness.
  • omegaWe review the terminology of decompression illness (DCI), investigations of residual symptoms of decompression sickness (DCS), and application of survival analysis for investigating DCI severity and resolution.
  • The method applies to a continuum of resolution times, allows for time varying information, can manage cases lost to follow-up (censored), and has potential for investigating questions such as optimal therapy and DCI severity.
  • Appropriate definitions of mild and serious manifestations are essential for computing probabilistic decompression procedures where severity determines the DCS probability that is acceptable.
  • Application of survival analysis to DCI data would require more specific case information than is commonly recorded.
  • [MeSH-major] Decompression Sickness / diagnosis. Severity of Illness Index

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19456008.001).
  • [ISSN] 0095-6562
  • [Journal-full-title] Aviation, space, and environmental medicine
  • [ISO-abbreviation] Aviat Space Environ Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


52. Rashid-Kolvear F, Pintilie M, Done SJ: Telomere length on chromosome 17q shortens more than global telomere length in the development of breast cancer. Neoplasia; 2007 Apr;9(4):265-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomere length on chromosome 17q shortens more than global telomere length in the development of breast cancer.
  • It is known that total telomere length is shorter in invasive breast cancer than in normal breast tissue but the status of individual telomere lengths has not been studied.
  • In this study we compared normal breast epithelium, duct carcinoma in situ (DCIS), and invasive duct carcinoma (IDC) from 18 patients.
  • Telomere length was specifically measured on chromosome 17q and was found to be shorter in DCIS and IDC than in normal breast epithelial cells, with more heterogeneity in telomere length in DCIS associated with IDC than in DCIS alone.
  • This finding indicates that telomere shortening is not simply the result of the end replication problem; otherwise, all telomeres should be subjected to the same rate of telomere shortening.
  • Our results suggest that the increased level of telomere shortening on 17q may be involved in chromosome instability and the progression of DCIS.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Carcinoma, Intraductal, Noninfiltrating / genetics. Chromosomes, Human, Pair 17 / genetics. Telomere / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1996 Nov 1;15(21):5928-35 [8918470.001]
  • [Cites] Cancer Res. 1996 Nov 15;56(22):5260-5 [8912866.001]
  • [Cites] Nat Genet. 1998 Jan;18(1):76-80 [9425906.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1340-9 [9552035.001]
  • [Cites] Hum Mol Genet. 1999 Jan;8(1):137-42 [9887342.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):551-7 [9973199.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):826-30 [10029071.001]
  • [Cites] Gene. 1999 May 17;232(1):97-106 [10333526.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Sep 24;263(2):361-5 [10491298.001]
  • [Cites] Neoplasia. 2005 Jun;7(6):614-22 [16036112.001]
  • [Cites] Neoplasia. 2006 Feb;8(2):136-42 [16611406.001]
  • [Cites] J Biol Chem. 2000 Nov 17;275(46):35665-8 [10986277.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):3826-31 [11274400.001]
  • [Cites] Cell. 2001 Oct 5;107(1):67-77 [11595186.001]
  • [Cites] Breast Cancer Res Treat. 2006 Sep;99(2):193-202 [16752076.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1751-6 [14578175.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):925-35 [14982846.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1807-14 [15143073.001]
  • [Cites] Mol Biol Cell. 2004 Aug;15(8):3709-18 [15181152.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Sep;85(18):6622-6 [3413114.001]
  • [Cites] Science. 1992 Sep 4;257(5075):1410-2 [1388286.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2978-84 [7911069.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3399-405 [7614479.001]
  • [Cites] Cancer Lett. 1996 Sep 10;106(2):155-61 [8844967.001]
  • [Cites] Eur J Cancer. 1997 Apr;33(5):787-91 [9282118.001]
  • (PMID = 17460770.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC1854852
  •  go-up   go-down


53. Hofvind S, Yankaskas BC, Bulliard JL, Klabunde CN, Fracheboud J: Comparing interval breast cancer rates in Norway and North Carolina: results and challenges. J Med Screen; 2009;16(3):131-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparing interval breast cancer rates in Norway and North Carolina: results and challenges.
  • OBJECTIVE: To compare interval breast cancer rates (ICR) between a biennial organized screening programme in Norway and annual opportunistic screening in North Carolina (NC) for different conceptualizations of interval cancer.
  • The rate of ductal carcinoma in situ was significantly lower in Norway than in NC for cases diagnosed in both the first and second year after screening.
  • The distributions of histopathological tumour size and lymph node involvement in invasive cases did not differ between the two regions for interval cancers diagnosed during the first year after screening.
  • CONCLUSION: Even when applying a common set of definitions of interval cancer, the ICR was lower in Norway than in NC.
  • Different definitions of interval cancer did not influence the ICR within Norway or NC.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19805754.001).
  • [ISSN] 1475-5793
  • [Journal-full-title] Journal of medical screening
  • [ISO-abbreviation] J Med Screen
  • [Language] eng
  • [Grant] United States / NCCDPHP CDC HHS / DP / NC U58 DP000123-02; United States / NCI NIH HHS / CA / U01-CA70040
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


54. Begum SM, Jara-Lazaro AR, Thike AA, Tse GM, Wong JS, Ho JT, Tan PH: Mucin extravasation in breast core biopsies--clinical significance and outcome correlation. Histopathology; 2009 Nov;55(5):609-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin extravasation in breast core biopsies--clinical significance and outcome correlation.
  • AIMS: To document the spectrum of lesions associated with mucin extravasation (ME) in breast core biopsy specimens, and to correlate with open surgical excisions.
  • Fibrocystic change (FC), atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS) were found in 21 (53.8%), 13 (33.3%) and four (10.3%) core biopsy specimens, respectively, with one (2.6%) consisting only of mucin pools.
  • On open biopsy, three cases underdiagnosed on core biopsy included FC that later disclosed ADH; one ADH lesion on core later upgraded to DCIS; and a case of mucin pools that revealed mucinous carcinoma on excision.
  • For calcified lesions that were completely removed on core biopsy, there were no malignant lesions discovered on open excision that had not already been diagnosed preoperatively.
  • When the entire radiological abnormality has been removed with large core mammotome biopsy specimens, surgery may potentially be avoided in histologically benign lesions, although such an approach requires further validation.
  • [MeSH-major] Biopsy, Needle. Breast Diseases / metabolism. Breast Diseases / pathology. Mucins / metabolism

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19912367.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


55. Manfrin E, Mariotto R, Remo A, Reghellin D, Dalfior D, Falsirollo F, Bonetti F: Is there still a role for fine-needle aspiration cytology in breast cancer screening? Experience of the Verona Mammographic Breast Cancer Screening Program with real-time integrated radiopathologic activity (1999-2004). Cancer; 2008 Apr 25;114(2):74-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there still a role for fine-needle aspiration cytology in breast cancer screening? Experience of the Verona Mammographic Breast Cancer Screening Program with real-time integrated radiopathologic activity (1999-2004).
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Fine-Needle. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology
  • [MeSH-minor] Aged. Cytological Techniques. Female. Humans. Italy / epidemiology. Mammography / methods. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer. 2008 Apr 25;114(2):65-6 [18327791.001]
  • (PMID = 18306357.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


56. Kawasaki T, Nakamura S, Sakamoto G, Murata S, Tsunoda-Shimizu H, Suzuki K, Takahashi O, Nakazawa T, Kondo T, Katoh R: Neuroendocrine ductal carcinoma in situ (NE-DCIS) of the breast--comparative clinicopathological study of 20 NE-DCIS cases and 274 non-NE-DCIS cases. Histopathology; 2008 Sep;53(3):288-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine ductal carcinoma in situ (NE-DCIS) of the breast--comparative clinicopathological study of 20 NE-DCIS cases and 274 non-NE-DCIS cases.
  • Kawasaki T, Nakamura S, Sakamoto G, Murata S, Tsunoda-shimizu H, Suzuki K, Takahashi O, Nakazawa T, Kondo T & Katoh R (2008) Histopathology53, 288-298Neuroendocrine ductal carcinoma in situ (NE-DCIS) of the breast - comparative clinicopathological study of 20 NE-DCIS cases and 274 non-NE-DCIS cases Aims: To clarify the clinicopathological significance of breast neuroendocrine ductal carcinoma in situ (NE-DCIS), i.e.
  • DCIS in which >50% of cells immunohistochemically express NE markers (chromogranin A and/or synaptophysin), 20 NE-DCIS were studied and the findings compared with those of 274 non-NE-DCIS.
  • METHODS AND RESULTS: NE-DCIS accounted for 6.8% of all DCIS.
  • Mean patient age was 50.4 years for NE-DCIS and 49.6 years for non-NE-DCIS (P = 0.66).
  • The main clinical presentation of NE-DCIS was a bloody nipple discharge, seen in 72%, significantly different from the 5% in non-NE-DCIS cases (P < 0.01).
  • Carcinoma was preoperatively diagnosed in 67% of NE-DCIS and 95% of non-NE-DCIS cases (P < 0.01).
  • NE-DCIS was histologically characterized by a predominantly solid growth of cancer cells with fine-granular cytoplasm and ovoid, or occasionally spindle-shaped nuclei.
  • Nuclear grades and Van Nuys classification were significantly lower for NE-DCIS than for non-NE-DCIS (P < 0.01).
  • The mean MIB-1 labelling index was 4.3% in NE-DCIS and 8.1% in non-NE-DCIS (P < 0.01).
  • Furthermore, NE-DCIS cases had significantly higher oestrogen and progesterone receptor and lower HER2 scores than non-NE-DCIS cases (P < 0.01).
  • CONCLUSIONS: NE-DCIS has characteristic clinicopathological features and can, therefore, be regarded as a distinct variant of DCIS.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Neuroendocrine / pathology


57. Chen CL, Chu JS, Su WC, Huang SC, Lee WY: Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX. Virchows Arch; 2010 Jul;457(1):53-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX.
  • Hypoxia and acidosis are microenvironmental selection forces during somatic evolution in breast carcinogenesis.
  • The effect of cobalt chloride (CoCl(2))-induced hypoxia on the expression of hypoxia-inducible factor (HIF)-1alpha, glucose transporter 1 (GLUT1), and carbonic anhydrase IX (CAIX) was assessed in breast cancer cells derived from primary sites (HCC1395 and HCC1937) and metastatic sites (MCF-7 and MDA-MB-231) by reverse transcriptase-polymerase chain reaction and immunoblotting.
  • We analyzed these proteins' expression in tissue samples from normal breast tissue, usual ductal hyperplasia (DH), atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS), and invasive ductal carcinoma (IDC) using immunohistochemistry.
  • CAIX mRNA expression was increased after CoCl(2)-induced hypoxia in all four breast cancer cell lines.
  • The expression of HIF-1alpha and GLUT1 proteins was increased after CoCl(2)-induced hypoxia in all breast cancer cell lines tested.
  • Hypoxia significantly increased CAIX protein expression in primary cancer cells but not in metastatic ones.
  • HIF-1alpha was not expressed in benign breast tissue, whereas it was significantly expressed in DH, ADH, DCIS, and IDC (p < 0.001).
  • GLUT1 and CAIX were expressed only in DCIS (56.8% and 25.0%) and IDC (44.1% and 30.5%), with higher expression in high grade DCIS than low/intermediate grade DCIS (79.2% vs. 30.0%, p = 0.001 and 37.5% vs. 10.0%, p = 0.036, respectively).
  • During breast carcinogenesis, the role of HIF-1alpha changes from response to proliferation to tumor progression.
  • GLUT1 expression (glycolytic phenotype) and CAIX expression (acid-resistant phenotype) may result in a powerful adaptive advantage and represent an aggressive phenotype.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Breast Neoplasms / metabolism. Carbonic Anhydrases / biosynthesis. Carcinoma in Situ / metabolism. Carcinoma, Ductal, Breast / metabolism. Glucose Transporter Type 1 / biosynthesis. Hypoxia-Inducible Factor 1, alpha Subunit / biosynthesis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. COBALT, ELEMENTAL .
  • Hazardous Substances Data Bank. COBALTOUS CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2009 Aug;29(8):3131-8 [19661326.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6212-20 [14559806.001]
  • [Cites] Oncogene. 1999 May 27;18(21):3199-204 [10359525.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1798-802 [9351550.001]
  • [Cites] Mutat Res. 1992 Aug;268(2):297-305 [1379335.001]
  • [Cites] Metabolism. 1999 Apr;48(4):422-31 [10206432.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3660-8 [11504747.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7259-66 [16103077.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):172-7 [15677538.001]
  • [Cites] J Biol Chem. 2001 Mar 23;276(12 ):9519-25 [11120745.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):309-14 [11181778.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):104-9 [17213826.001]
  • [Cites] BMC Cancer. 2009 Jun 09;9:175 [19505343.001]
  • [Cites] Cancer Metastasis Rev. 2007 Jun;26(2):299-310 [17415526.001]
  • [Cites] J Theor Biol. 2007 Feb 21;244(4):703-13 [17055536.001]
  • [Cites] Nature. 1996 Jan 4;379(6560):88-91 [8538748.001]
  • [Cites] Trends Pharmacol Sci. 2006 Nov;27(11):566-73 [16996620.001]
  • [Cites] Cell Cycle. 2004 Feb;3(2):164-7 [14712082.001]
  • [Cites] Breast Cancer Res Treat. 2003 Sep;81(1):61-9 [14531498.001]
  • [Cites] Biochem Pharmacol. 2007 Mar 1;73(5):694-708 [17169330.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):721-32 [13130303.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1451-8 [17245699.001]
  • [Cites] J Appl Physiol (1985). 2000 Apr;88(4):1474-80 [10749844.001]
  • [Cites] Zhonghua Gan Zang Bing Za Zhi. 2007 Sep;15(9):654-7 [17903365.001]
  • [Cites] J Bioenerg Biomembr. 1997 Aug;29(4):355-64 [9387096.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5216-23 [16707446.001]
  • [Cites] Breast Cancer Res Treat. 2003 Sep;81(2):137-47 [14572156.001]
  • [Cites] Br J Cancer. 2007 Sep 3;97(5):646-53 [17687336.001]
  • [Cites] Br J Cancer. 2009 Jan 27;100(2):405-11 [19165203.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12 (21):6421-31 [17085655.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):377-84 [18055005.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4469-77 [12154057.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):1164-7 [8640778.001]
  • [Cites] Biochim Biophys Acta. 2005 May 25;1729(1):41-9 [15833446.001]
  • (PMID = 20526721.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antimutagenic Agents; 0 / Glucose Transporter Type 1; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; 0 / SLC2A1 protein, human; 3G0H8C9362 / Cobalt; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrase IX; EC 4.2.1.1 / Carbonic Anhydrases; EVS87XF13W / cobaltous chloride
  •  go-up   go-down


58. Solin LJ, Fourquet A, Vicini FA, Taylor M, Olivotto IA, Haffty B, Strom EA, Pierce LJ, Marks LB, Bartelink H, McNeese MD, Jhingran A, Wai E, Bijker N, Campana F, Hwang WT: Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer; 2005 Mar 15;103(6):1137-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast.
  • BACKGROUND: Ductal carcinoma in situ (DCIS) is detected most commonly on routine screening mammography in the asymptomatic patient, and has a long natural history.
  • The objective of the current study was to determine the long-term outcome after breast-conservation surgery followed by definitive breast irradiation for women with mammographically detected DCIS of the breast.
  • METHODS: In total, 1003 women with unilateral, mammographically detected DCIS of the breast underwent breast-conserving surgery followed by definitive breast irradiation.
  • In total, there were 100 local failures (10%) in the treated breast.
  • CONCLUSIONS: The current results support the use of breast-conserving surgery followed by definitive breast irradiation for the treatment of patients with mammographically detected DCIS of the breast.
  • [MeSH-major] Breast Neoplasms / therapy. Carcinoma in Situ / therapy. Carcinoma, Ductal, Breast / therapy. Mammography / methods. Mastectomy, Segmental. Neoplasm Recurrence, Local / epidemiology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15674853.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


59. Streckfus CF, Mayorga-Wark O, Arreola D, Edwards C, Bigler L, Dubinsky WP: Breast cancer related proteins are present in saliva and are modulated secondary to ductal carcinoma in situ of the breast. Cancer Invest; 2008 Mar;26(2):159-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer related proteins are present in saliva and are modulated secondary to ductal carcinoma in situ of the breast.
  • OBJECTIVE: The objective of this study was to determine if protein-by-products secondary to cancer related oncogenes appear in the saliva of breast cancer patients.
  • One pooled specimen was from healthy women, another pooled specimen from women diagnosed with a benign breast tumor and the other one pooled specimen was from women diagnosed with ductal carcinoma in situ (DCIS).
  • Forty-nine proteins were differentially expressed between the healthy control pool and the benign and cancer patient groups.
  • CONCLUSIONS: The study suggests that saliva is a fluid suffused with solubilized by-products of oncogenic expression and that these proteins may be modulated secondary to DCIS.
  • Additionally, there may be salivary protein profiles that are unique to both DCIS and fibroadenoma tumors.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Fibroadenoma / metabolism. Neoplasm Proteins / metabolism. Saliva / metabolism. Salivary Proteins and Peptides / metabolism
  • [MeSH-minor] Female. Humans. Middle Aged. Proteomics. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18259946.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Salivary Proteins and Peptides
  •  go-up   go-down


60. Guo XJ, Chen L, Lang RG, Fan Y, Fu L: [Relationship between lymph node metastasis and pathologic features of invasive micropapillary carcinoma of breast]. Zhonghua Bing Li Xue Za Zhi; 2006 Jan;35(1):8-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between lymph node metastasis and pathologic features of invasive micropapillary carcinoma of breast].
  • OBJECTIVE: To investigate the relationship between lymph node metastasis and pathologic features of invasive micropapillary carcinoma (IMPC) of the breast.
  • The metastatic foci in lymph node were all IMPC or mainly IMPC. (5) Fourteen of twenty-eight cases (14/28, 50%) of IMPC containing ductal carcinoma in-situ (DCIS) were DCIS of micropapillary type.
  • Micropapillary type DCIS may be the early stage of IMPC.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Papillary / pathology. Lymph Nodes / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608641.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor C; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  •  go-up   go-down


61. Shafiq J, Delaney G, Barton MB: An evidence-based estimation of local control and survival benefit of radiotherapy for breast cancer. Radiother Oncol; 2007 Jul;84(1):11-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An evidence-based estimation of local control and survival benefit of radiotherapy for breast cancer.
  • BACKGROUND AND PURPOSE: Survival benefits from radiotherapy for breast cancer described in randomised trials represent only those patients eligible for trials.
  • We estimated the benefit of radiotherapy as an adjuvant treatment for the entire population of breast cancer patients if evidence-based treatment guidelines were followed.
  • The data were incorporated into the optimal radiotherapy utilization tree that we previously reported for all categories of breast cancer patients and overall local control and survival benefits were estimated.
  • RESULTS: The gains in 10-year local control and overall survival from optimal treatment of all breast cancer patients were 11.1% (95% CI 10.8-11.2%) and 3.1% (95% CI 3.0-3.4%), respectively.
  • The stage-based estimates in local control and survival benefit were: 8% and 0% for Ductal Carcinoma in situ (DCIS), 12% and 2% for stage I-II cancers and 13% and 20% for stage III cancers.
  • CONCLUSIONS: Our model was able to estimate the contribution of radiotherapy in breast cancer treatment if all patients were treated according to the recommended guidelines.
  • These estimates could be used to benchmark population-based survival reports and to assess the cost-effectiveness of radiotherapy for breast cancer treatment.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Carcinoma, Ductal / radiotherapy. Carcinoma, Intraductal, Noninfiltrating / radiography. Neoplasm Recurrence, Local
  • [MeSH-minor] Cost-Benefit Analysis. Evidence-Based Medicine. Female. Humans. Mastectomy. Neoplasm Staging. Practice Guidelines as Topic. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17399830.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


62. Vincent-Salomon A, Lucchesi C, Gruel N, Raynal V, Pierron G, Goudefroye R, Reyal F, Radvanyi F, Salmon R, Thiery JP, Sastre-Garau X, Sigal-Zafrani B, Fourquet A, Delattre O, breast cancer study group of the Institut Curie: Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res; 2008 Apr 1;14(7):1956-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast.
  • PURPOSE: To gain insight into genomic and transcriptomic subtypes of ductal carcinomas in situ of the breast (DCIS).
  • EXPERIMENTAL DESIGN: We did a combined phenotypic and genomic analysis of a series of 57 DCIS integrated with gene expression profile analysis for 26 of the 57 cases.
  • RESULTS: Thirty-two DCIS exhibited a luminal phenotype; 21 were ERBB2 positive, and 4 were ERBB2/estrogen receptor (ER) negative with 1 harboring a bona fide basal-like phenotype.
  • Based on a CGH analysis, genomic types were identified in this series of DCIS with the 1q gain/16q loss combination observed in 3 luminal DCIS, the mixed amplifier pattern including all ERBB2, 12 luminal and 2 ERBB2(-)/ER(-) DCIS, and the complex copy number alteration profile encompassing 14 luminal and 1 ERBB2(-)/ER(-) DCIS.
  • Unsupervised analysis of gene expression profiles of 26 of the 57 DCIS showed that luminal and ERBB2-amplified, ER-negative cases clustered separately.
  • Strikingly, amplicons but also low copy number changes especially on 1q, 8q, and 16q in DCIS regulated the expression of a subset of genes in a very similar way to that recently described in invasive ductal carcinomas.
  • CONCLUSIONS: These combined approaches show that the molecular heterogeneity of breast ductal carcinomas exists already in in situ lesions and further indicate that DCIS and invasive ductal carcinomas share genomic alterations with a similar effect on gene expression profile.
  • [MeSH-major] Biomarkers, Tumor / genetics. Breast Neoplasms / genetics. Carcinoma, Intraductal, Noninfiltrating / genetics. Gene Expression Profiling. Genomics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18381933.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Investigator] Asselain B; Aurias A; Barillot E; Bollet M; Campana F; Cottu P; de Cremoux P; Diéras V; Mignot L; Pierga JY; Poupon MF; Stoppa-Lyonnet D; Tardivon A; Thibault F; This P
  •  go-up   go-down


63. Doshi DJ, March DE, Crisi GM, Coughlin BF: Complex cystic breast masses: diagnostic approach and imaging-pathologic correlation. Radiographics; 2007 Oct;27 Suppl 1:S53-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complex cystic breast masses: diagnostic approach and imaging-pathologic correlation.
  • Complex cystic breast masses demonstrate both anechoic (cystic) and echogenic (solid) components at ultrasonography (US).
  • Numerous pathologic entities may produce complex cystic breast lesions or may be associated with them, and biopsy is usually indicated.
  • Common benign findings include fibrocystic changes, intraductal or intracystic papilloma without atypia, and fibroadenoma.
  • Common atypical findings include atypical ductal hyperplasia, atypical papilloma, atypical lobular hyperplasia, and lobular carcinoma in situ.
  • Malignant findings include ductal carcinoma in situ, infiltrating ductal carcinoma, and infiltrating lobular carcinoma.
  • [MeSH-major] Breast Diseases / diagnosis. Cysts / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2007.
  • (PMID = 18180235.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


64. Kuhl C, Weigel S, Schrading S, Arand B, Bieling H, König R, Tombach B, Leutner C, Rieber-Brambs A, Nordhoff D, Heindel W, Reiser M, Schild HH: Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol; 2010 Mar 20;28(9):1450-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial.
  • PURPOSE: We investigated the respective contribution (in terms of cancer yield and stage at diagnosis) of clinical breast examination (CBE), mammography, ultrasound, and quality-assured breast magnetic resonance imaging (MRI), used alone or in different combination, for screening women at elevated risk for breast cancer.
  • In a subgroup of 371 women, additional half-yearly ultrasound and CBE was performed more than 869 screening rounds.
  • RESULTS: Twenty-seven women were diagnosed with breast cancer: 11 ductal carcinoma in situ (41%) and 16 invasive cancers (59%).
  • All cancers were detected during annual screening; no interval cancer occurred; no cancer was identified during half-yearly ultrasound.
  • The cancer yield of ultrasound (6.0 of 1,000) and mammography (5.4 of 1,000) was equivalent; it increased nonsignificantly (7.7 of 1,000) if both methods were combined.
  • Cancer yield achieved by MRI alone (14.9 of 1,000) was significantly higher; it was not significantly improved by adding mammography (MRI plus mammography: 16.0 of 1,000) and did not change by adding ultrasound (MRI plus ultrasound: 14.9 of 1,000).
  • CONCLUSION: In women at elevated familial risk, quality-assured MRI screening shifts the distribution of screen-detected breast cancers toward the preinvasive stage.
  • In women undergoing quality-assured MRI annually, neither mammography, nor annual or half-yearly ultrasound or CBE will add to the cancer yield achieved by MRI alone.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Genetic Predisposition to Disease. Humans. Magnetic Resonance Imaging. Mammography. Mass Screening. Middle Aged. Physical Examination. Prospective Studies. Risk Factors. Ultrasonography

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 Mar 20;28(9):1441-5 [20177020.001]
  • [CommentIn] J Clin Oncol. 2010 Oct 20;28(30):e607-8; author reply e609-10 [20855835.001]
  • [CommentIn] Womens Health (Lond Engl). 2010 Jul;6(4):509-10 [20597614.001]
  • (PMID = 20177029.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


65. Li Q, Chow AB, Mattingly RR: Three-dimensional overlay culture models of human breast cancer reveal a critical sensitivity to mitogen-activated protein kinase kinase inhibitors. J Pharmacol Exp Ther; 2010 Mar;332(3):821-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional overlay culture models of human breast cancer reveal a critical sensitivity to mitogen-activated protein kinase kinase inhibitors.
  • We studied the effects of targeted agents and doxorubicin on 2D and 3D cultures of human breast cell lines that represent the progression from normal epithelia (modeled by MCF10A cells) through hyperplastic variants to a dysplastic/carcinoma phenotype (MCF10.DCIS cells), variants transformed by expression of activated Ras, and also a basal-subtype breast carcinoma cell line (MDA-MB-231).
  • The results showed the expected relative resistance to the cytotoxic agent doxorubicin in 3D cultures, with greater resistance in normal and hyperplastic cells than in carcinoma models.
  • In 3D culture, the normal and hyperplastic models exhibited some resistance, whereas the carcinoma models became far more sensitive to MEK inhibition.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Signal. 2001 Jul;13(7):499-505 [11516625.001]
  • [Cites] Crit Rev Oncol Hematol. 2000 Nov-Dec;36(2-3):193-207 [11033306.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 2;94(19):1494-503 [12359858.001]
  • [Cites] J Cell Sci. 2003 Jun 15;116(Pt 12):2377-88 [12766184.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • [Cites] Semin Oncol. 2003 Oct;30(5 Suppl 16):105-16 [14613031.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4585-92 [15231670.001]
  • [Cites] J Natl Cancer Inst. 1996 Sep 18;88(18):1285-96 [8797768.001]
  • [Cites] J Biol Chem. 1998 Jul 17;273(29):18623-32 [9660836.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14821-6 [9843973.001]
  • [Cites] Anticancer Drug Des. 1999 Apr;14(2):153-68 [10405642.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4456-62 [15483017.001]
  • [Cites] Cancer Lett. 2005 Jan 20;217(2):171-80 [15617834.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Jan;316(1):456-65 [16239399.001]
  • [Cites] Breast Cancer Res Treat. 2006 Mar;96(2):169-76 [16331349.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3291-310 [17496923.001]
  • [Cites] Biochim Biophys Acta. 2007 Aug;1773(8):1263-84 [17126425.001]
  • [Cites] Biochem J. 2007 Dec 15;408(3):297-315 [17850214.001]
  • [Cites] Int J Radiat Biol. 2007 Nov-Dec;83(11-12):849-71 [18058370.001]
  • [Cites] Genes Dev. 2007 Dec 15;21(24):3214-31 [18079171.001]
  • [Cites] Neoplasia. 2008 Apr;10(4):314-29 [18392133.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2139-46 [18390968.001]
  • [Cites] Neoplasia. 2008 Dec;10(12):1444-58 [19048123.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8010-8 [19088017.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):565-72 [19147570.001]
  • [Cites] Oncogene. 2009 Jan 22;28(3):461-8 [18978815.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1487-95 [19228750.001]
  • [Cites] Clin Cancer Res. 2009 Jul 15;15(14):4649-64 [19567590.001]
  • [Cites] Breast Cancer Res Treat. 2000 Jul;62(1):51-62 [10989985.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):205-16 [12242153.001]
  • (PMID = 19952304.001).
  • [ISSN] 1521-0103
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01-CA131990; United States / NCI NIH HHS / CA / P30-CA22453; United States / NIEHS NIH HHS / ES / P30-ES06639; United States / NCI NIH HHS / CA / R01 CA131990; United States / NIEHS NIH HHS / ES / P30 ES006639; United States / NCI NIH HHS / CA / P30 CA022453
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide; 0 / Androstadienes; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Butadienes; 0 / Nitriles; 0 / U 0126; 80168379AG / Doxorubicin; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; XVA4O219QW / wortmannin
  • [Other-IDs] NLM/ PMC2835447
  •  go-up   go-down


66. Sahin FI, Yilmaz Z, Yagmurdur MC, Atac FB, Ozdemir BH, Karakayali H, Demirhan B, Haberal M: Clinical findings and HER-2/neu gene amplification status of breast carcinoma patients. Pathol Oncol Res; 2006;12(4):211-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical findings and HER-2/neu gene amplification status of breast carcinoma patients.
  • The study group was derived from the archival materials of 48 invasive intraductal breast cancer patients who had undergone partial mastectomy/ axillary dissection.
  • All patients included in the study had clinically T1-2N0M0 invasive ductal carcinoma.
  • To detect HER-2/neu status, fluorescent in situ hybridization was performed using a HER-2/neu locus-specific probe.
  • No significant difference was observed between groups for distant metastasis in a 5-year follow-up period.
  • The extensive intraductal component ratio was the highest in group 3 (P=0.04).
  • Our results show that HER-2/neu signal ratio increases with lymphovascular invasion, an extensive intraductal component, irregular growth pattern and axillary metastasis in clinically T1-2N0M0 invasive ductal carcinoma of the breast.
  • [MeSH-major] Breast Neoplasms / genetics. Gene Amplification. Neoplasm Invasiveness / pathology. Receptor, ErbB-2 / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Axilla / pathology. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / secondary. Carcinoma, Lobular / genetics. Carcinoma, Lobular / secondary. Female. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization, Fluorescence. Lymphatic Metastasis. Middle Aged. Prognosis. Receptors, Estrogen / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncologist. 2003;8(4):307-25 [12897328.001]
  • [Cites] Pathol Oncol Res. 2005;11(4):224-8 [16388319.001]
  • [Cites] Breast. 2001 Feb;10(1):67-77 [14965564.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Dec;155(2):143-8 [15571800.001]
  • [Cites] J Pathol. 2003 Apr;199(4):418-23 [12635131.001]
  • [Cites] MedGenMed. 2003 Nov 11;5(4):20 [14745367.001]
  • [Cites] Lab Invest. 2002 Aug;82(8):1007-14 [12177239.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8452-8 [11731427.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1398-403 [12196365.001]
  • [Cites] Am J Clin Pathol. 2004 Jan;121(1):70-7 [14750243.001]
  • [Cites] J Pathol. 2003 Apr;199(4):411-7 [12635130.001]
  • [Cites] Indian J Cancer. 2004 Oct-Dec;41(4):152-8 [15659867.001]
  • [Cites] APMIS. 2003 Mar;111(3):444-50 [12752225.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3651-64 [11054438.001]
  • [Cites] Clin Cancer Res. 1998 Jan;4(1):7-12 [9516946.001]
  • (PMID = 17189983.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Receptors, Estrogen; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


67. Bose S, Chandran S, Mirocha JM, Bose N: The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol; 2006 Feb;19(2):238-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Akt pathway in human breast cancer: a tissue-array-based analysis.
  • This study was conducted to determine the status of the Akt pathway in human breast cancers and to study the relationship between the different component proteins.
  • Expression levels of PTEN, phosphorylated forms of the constituent proteins (Akt, FKHR, mTOR, and S6) and cyclin D1 were evaluated by immunohistochemistry, on consecutive sections from a tissue microarray containing 145 invasive breast cancers and 140 pure ductal carcinomas in-situ.
  • Aberrant expression was correlated statistically with tumor characteristics and disease outcome.
  • The Akt pathway was found to be activated early in breast cancer, in the in-situ stage.
  • In all, 33, 15, 32, and 60% of ductal carcinoma in-situ showed overexpression of Akt, FKHR, mTOR, and cyclin D1.
  • Expression levels of PTEN and S6 were significantly different in in-situ and invasive cancers, indicating association with disease progression.
  • Loss of PTEN was noted in 11% of in-situ as compared to 26% of invasive cancers, while S6 overexpression was seen in 47% in-situ and in 72% invasive cancers.
  • High-grade carcinomas were associated with PTEN loss, while low-grade carcinomas with good prognostic features showed cyclin D1 overexpression and were associated with longer disease free survival.
  • Additionally, cancers with mTOR overexpression showed a three times greater risk for disease recurrence.
  • Overall, a large proportion of in-situ and invasive breast cancers overexpressed cyclinD1 and S6.
  • [MeSH-major] Breast Neoplasms / pathology. Proto-Oncogene Proteins c-akt / physiology. Signal Transduction
  • [MeSH-minor] Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / physiopathology. Cyclin D1 / analysis. Disease Progression. Female. Humans. Immunohistochemistry. Logistic Models. Multivariate Analysis. Neoplasm Invasiveness. PTEN Phosphohydrolase / analysis. Protein Kinases / analysis. Ribosomal Protein S6 Kinases / analysis. Survival Analysis. TOR Serine-Threonine Kinases. Tissue Array Analysis / methods


68. Katz SJ, Lantz PM, Janz NK, Fagerlin A, Schwartz K, Liu L, Deapen D, Salem B, Lakhani I, Morrow M: Surgeon perspectives about local therapy for breast carcinoma. Cancer; 2005 Nov 1;104(9):1854-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgeon perspectives about local therapy for breast carcinoma.
  • BACKGROUND: Geographic variations in the use of mastectomy and the use of radiation therapy (RT) after breast-conserving surgery (BCS) have motivated concerns that surgeons are not uniformly adhering to treatment standards.
  • METHODS: The authors surveyed attending surgeons of a population-based sample of patients with breast carcinoma diagnosed in Detroit and Los Angeles from December 2001 to January 2003 (n = 365; response rate, 80.0%).
  • RESULTS: On average, surgeons reported that they devoted 31.3% of their total practice to breast carcinoma.
  • Approximately one-half of surgeons practiced in a community hospital setting, whereas 18.8% practiced in a cancer center.
  • Compared to low volume surgeons, high volume surgeons were more likely to favor BCS with RT for invasive breast carcinoma (60.8%, 74.0%, and 87.2% for low, moderate, and high volume surgeons, respectively, P < 0.001).
  • In a ductal carcinoma in situ scenario, 35.0% of surgeons favored BCS without RT and 61.0% favored BCS with RT.
  • Opinions regarding the role of RT after BCS varied by geographic site, surgeon volume, and patient age.
  • [MeSH-major] Attitude of Health Personnel. Breast Neoplasms / surgery. General Surgery. Mastectomy. Mastectomy, Segmental. Professional Practice

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 16161056.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / CA / R01 CA8837-A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


69. Apple SK, Matin M, Olsen EP, Moatamed NA: Significance of lobular intraepithelial neoplasia at margins of breast conservation specimens: a report of 38 cases and literature review. Diagn Pathol; 2010;5:54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of lobular intraepithelial neoplasia at margins of breast conservation specimens: a report of 38 cases and literature review.
  • BACKGROUND: Presence of lobular intraepithelial neoplasia (LIN) is not routinely reported as part of margin assessment in breast conservation therapy (BCT) as in ductal carcinoma in situ (DCIS).
  • METHODS: We retrospectively reviewed a total of 1,334 BCT at a single institution in a 10 year period.
  • Inclusion criteria are positive margin with LIN from primary BCT containing invasive and/or in situ carcinoma with comparison to the negative control group who had similar diseases with negative margin for LIN.
  • RESULTS: We identified 38 cases (2.8%) with LIN either lobular carcinoma in situ/atypical lobular hyperplasia (LCIS/ALH) at a margin on initial BCT with 36% recurrence rate.
  • Out of 21 patients who had re-excisions, 12 (57%) had residual invasive carcinoma or DCIS, three (14%) had pleomorphic LCIS and 4 (19%) showed residual classic type LCIS.
  • 71% had significant residual disease (local recurrence) and 29% had no residual disease.
  • CONCLUSIONS: LIN found at a margin on BCT showed a significant recurrent ipsilateral disease.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma in Situ / surgery. Carcinoma, Intraductal, Noninfiltrating / surgery. Carcinoma, Lobular / surgery. Mastectomy, Segmental. Neoplasm Recurrence, Local. Neoplasm, Residual
  • [MeSH-minor] Female. Humans. Hyperplasia. Los Angeles. Mammography. Neoplasm Invasiveness. Retrospective Studies. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1998 Jul;153(1):5-9 [9665458.001]
  • [Cites] J Pathol. 1997 Dec;183(4):404-11 [9496256.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):365-71 [16965988.001]
  • [Cites] Ann Surg Oncol. 2008 Aug;15(8):2263-71 [18506537.001]
  • [Cites] Eur J Surg Oncol. 2010 Feb;36(2):176-81 [19647390.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1072-7 [10699897.001]
  • [Cites] Breast Cancer Res Treat. 2000 Aug;62(3):197-210 [11072784.001]
  • [Cites] Breast Cancer. 2000;7(4):341-4 [11114862.001]
  • [Cites] Cancer. 2001 May 15;91(10):1862-9 [11346867.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):738-47 [11550142.001]
  • [Cites] Breast J. 2002 Sep-Oct;8(5):263-8 [12199752.001]
  • [Cites] Am Surg. 2004 Sep;70(9):818-21 [15481302.001]
  • [Cites] Cancer. 1978 Aug;42(2):737-69 [209887.001]
  • [Cites] Am J Surg Pathol. 1978 Sep;2(3):225-51 [210682.001]
  • [Cites] Hum Pathol. 1991 Dec;22(12):1232-9 [1748429.001]
  • [Cites] N Engl J Med. 1993 Jun 3;328(22):1581-6 [8292119.001]
  • [Cites] J Surg Oncol. 1998 Jan;67(1):41-6 [9457256.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):28-34 [16329136.001]
  • (PMID = 20727142.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2936385
  •  go-up   go-down


70. Intra M, Rotmensz N, Veronesi P, Colleoni M, Iodice S, Paganelli G, Viale G, Veronesi U: Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European institute of oncology on 854 patients in 10 years. Ann Surg; 2008 Feb;247(2):315-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European institute of oncology on 854 patients in 10 years.
  • OBJECTIVE: The aim of this study is to assess the role of sentinel lymph node (SLN) biopsy in patients with pure ductal carcinoma in situ of the breast (DCIS) as a rationale for recommending the best managing option for the treatment of such patients in daily practice.
  • SUMMARY BACKGROUND DATA: DCIS cannot give rise to axillary metastases by definition.
  • The role of SLN biopsy in the management of DCIS has not yet been established.
  • METHODS: From March 1996 to September 2006, 854 patients with pure DCIS underwent SLN biopsy at the European Institute of Oncology.
  • RESULTS: SLN metastases were detected in 12 (1.4%) DCIS patients.
  • CONCLUSIONS: Because of the low prevalence of metastatic involvement, SLN biopsy should not be considered a standard procedure in the treatment of all patients with DCIS.
  • The sole criteria for proposing SLN biopsy in DCIS should be when there exists any uncertainty regarding the presence of invasive foci at definitive histology.
  • [MeSH-major] Academies and Institutes. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / secondary. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy / standards
  • [MeSH-minor] Adult. Aged. Axilla. Biopsy, Fine-Needle. Europe. Female. Follow-Up Studies. Humans. Lymph Node Excision. Lymphatic Metastasis. Medical Oncology. Middle Aged. Neoplasm Staging / methods. Prognosis. Reproducibility of Results. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18216539.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Emanuel PO, de Vinck D, Waldorf HA, Phelps RG: Recurrent endocrine mucin-producing sweat gland carcinoma. Ann Diagn Pathol; 2007 Dec;11(6):448-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent endocrine mucin-producing sweat gland carcinoma.
  • Endocrine mucin-producing sweat gland carcinoma is a rare skin tumor that most commonly involves the eyelid of elderly women.
  • Morphologically and immunohistochemically, it is analogous to endocrine ductal carcinoma in situ of the breast and mammary solid papillary carcinoma; also, like the analogous breast lesion, there is an often associated invasive mucinous carcinoma with neuroendocrine differentiation.
  • We describe the case of a 65-year-old woman with endocrine mucin-producing sweat gland carcinoma of the eyelid that recurred 3 years after an apparently complete excision.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Eyelid Neoplasms / pathology. Mucins / biosynthesis. Neoplasm Recurrence, Local / pathology. Sweat Gland Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18022131.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


72. Van Houtte P, Bourgois N, Renard F, Huget P, D'hoore W, Scalliet P, Belgian Federal College of Radiotherapy: A federal audit of the Belgian radiotherapy departments in breast cancer treatment. Radiother Oncol; 2007 May;83(2):178-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A federal audit of the Belgian radiotherapy departments in breast cancer treatment.
  • BACKGROUND: The Belgian Federal College of Radiotherapy carried out an external audit of breast cancer patient documentation in the 26 Belgian radiotherapy centres.
  • METHODS: Two experienced radiation oncologists site-visited the departments over a 6 month period (Sept. 2003-Feb.
  • FINDINGS: Three hundred and eighty-nine patients files were reviewed, for a total of 399 breast cancers (10 patients with bilateral cancer).
  • Breast conservative surgery (BCS) was used in 71%; radical mastectomy in 29%.
  • 5.2% were treated for DCIS, 61.6% for pT1, 28.2% for pT2 and 5% for pT3-4.
  • Data regarding resection margins were specified to be free in 76.2%, tangential in 12% (within 2 mm) and positive for DCIS in 3.8% or invasive cancer in 1.5% (no information, on margins in 6.5%).
  • All radiotherapy prescriptions were in line with evidence-based standards of therapy (i.e., irradiation of breast after BCS or after mamectomy (in case of pN+), but one.
  • In addition, the quality of surgery (assessed by margin clearance) and of pathological reports was excellent, whatever the institution of origin (teaching vs. non-teaching, private vs. public).
  • All indications were evidence-based; there was no overuse of radiotherapy in early breast cancer treatment.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Radiation Oncology / standards

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17470379.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Ireland
  •  go-up   go-down


73. Ho BC, Tan PH: Flat epithelial atypia: concepts and controversies of an intraductal lesion of the breast. Pathology; 2005 Apr;37(2):105-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flat epithelial atypia: concepts and controversies of an intraductal lesion of the breast.
  • Image-guided biopsies of the breast play an integral role in the diagnostic evaluation of mammographically detected calcifications.
  • Apart from cancer, on these biopsies we are increasingly recognising a hitherto poorly categorised group of benign to atypical entities collectively known as columnar cell lesions.
  • There is emerging evidence to suggest that flat epithelial atypia may represent a precursor of or the earliest morphologically recognisable form of low-grade ductal carcinoma in situ.
  • In addition, these lesions are often associated with tubular carcinomas and lobular neoplasia.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Epithelial Cells / pathology. Precancerous Conditions / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16028837.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 27
  •  go-up   go-down


74. Raica M, Cîmpean AM, Meche A, Alexa A, Suciu C, Mureşan A: Analysis of the immunohistochemical expression of mammaglobin A in primary breast carcinoma and lymph node metastasis. Rom J Morphol Embryol; 2009;50(3):341-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the immunohistochemical expression of mammaglobin A in primary breast carcinoma and lymph node metastasis.
  • Few data are available about the immunohistochemical expression of this marker in mammary carcinoma and about the significance of the positive reaction.
  • Our purpose was to investigate the sensitivity of the mammaglobin expression in breast cancer and to determine its correlations with conventional prognostic parameters.
  • There were investigated 47 patients with breast carcinoma, and slides from paraffin blocks were stained with an antibody against mammaglobin.
  • Positive reaction for mammaglobin was found in the normal mammary tissue adjacent to the tumor in all cases, in 78.72% primary breast carcinoma, and in 58.06% of cases with lymph node metastases.
  • A significant correlation was found between the mammaglobin expression in the primary tumor, grade, and lymph node status, but not with the age of the patient, pathologic subtype of carcinoma and stage of the tumor.
  • The ductal in situ carcinoma associated to the invasive tumor did not influence significantly the prognostic value of mammaglobin expression.
  • Out results suggest that mammaglobin is a sensitive marker of breast carcinoma, it defines a subgroup of patients with better prognosis and is a useful method to detect breast cancer metastases.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Lymphatic Metastasis / pathology. Neoplasm Proteins / metabolism. Uteroglobin / metabolism
  • [MeSH-minor] Adult. Aged. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Female. Humans. Immunohistochemistry. Mammaglobin A. Middle Aged. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19690758.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


75. Hildick-Smith D, Behan M, Haworth P, Rana B, Thomas M: Patent foramen ovale closure without echocardiographic control: use of "standby" intracardiac ultrasound. JACC Cardiovasc Interv; 2008 Aug;1(4):387-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients were excluded from standby ICE if they had adverse anatomical features on their diagnostic transoesophageal echocardiogram, a device other than Amplatzer (AGA Medical, Plymouth, Minnesota), STARflex (NMT Medical, Boston, Massachusetts), or BioSTAR (NMT Medical) were to be used, or they were in a clinical trial demanding ICE/transesophageal echocardiography.
  • Primary indication for PFO closure was stroke (n = 46, 65%), transient ischemic attack (n = 22, 31%), or decompression illness (n = 2, 3%).

  • Genetic Alliance. consumer health - Patent Foramen Ovale.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JACC Cardiovasc Interv. 2009 Apr;2(4):369; author reply 369-70 [19463456.001]
  • [CommentIn] JACC Cardiovasc Interv. 2008 Aug;1(4):392-4 [19463335.001]
  • (PMID = 19463334.001).
  • [ISSN] 1876-7605
  • [Journal-full-title] JACC. Cardiovascular interventions
  • [ISO-abbreviation] JACC Cardiovasc Interv
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


76. Ganz PA: Quality-of-life issues in patients with ductal carcinoma in situ. J Natl Cancer Inst Monogr; 2010;2010(41):218-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality-of-life issues in patients with ductal carcinoma in situ.
  • Ductal carcinoma in situ (DCIS) as we know it today is a clinical entity that is primarily discovered through the finding of microscopic calcifications on a screening mammogram.
  • Asymptomatic women who are found to have DCIS receive treatments that are similar to women with invasive breast cancer and experience substantial psychological distress in spite of having an excellent prognosis and normal life expectancy.
  • More research is needed to determine the best way to communicate with women about this condition and to match the extent of treatment with the risk of serious future disease.
  • Clinical and research efforts should focus on reducing the anxiety and psychological distress associated with the diagnosis of DCIS.
  • [MeSH-major] Breast Neoplasms / psychology. Carcinoma, Intraductal, Noninfiltrating / psychology. Quality of Life
  • [MeSH-minor] Adult. Aged. Anxiety. Attitude to Health. Chemotherapy, Adjuvant / adverse effects. Chemotherapy, Adjuvant / psychology. Combined Modality Therapy. Cost of Illness. Disease Progression. Fear. Female. Humans. Life Expectancy. Mastectomy / adverse effects. Mastectomy / psychology. Middle Aged. Multicenter Studies as Topic / statistics & numerical data. Prognosis. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / psychology. Randomized Controlled Trials as Topic / statistics & numerical data. Risk. Self Concept. Stress, Psychological / etiology. Stress, Psychological / prevention & control

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20956834.001).
  • [ISSN] 1745-6614
  • [Journal-full-title] Journal of the National Cancer Institute. Monographs
  • [ISO-abbreviation] J. Natl. Cancer Inst. Monographs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  •  go-up   go-down


77. Guan H, Sun Y, Zan Q, Xu M, Li Y, Zhou J, He E, Eriksson S, Wen W, Skog S: Thymidine kinase 1 expression in atypical ductal hyperplasia significantly differs from usual ductal hyperplasia and ductal carcinoma in situ: A useful tool in tumor therapy management. Mol Med Rep; 2009 Nov-Dec;2(6):923-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymidine kinase 1 expression in atypical ductal hyperplasia significantly differs from usual ductal hyperplasia and ductal carcinoma in situ: A useful tool in tumor therapy management.
  • In studies using immunohistochemistry, it was reported to be a more useful proliferation marker than Ki-67 and PCNA in breast, lung and colorectal carcinoma.
  • In this study, we extend the work of prior breast carcinoma studies by investigating the expression of TK1 in 132 patients with usual ductal hyperplasia (UDH), atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC).
  • The expression of TK1 was found to be significantly increased in the breast ductal carcinomas in the following manner: UDH<ADH<DCIS<IDC.
  • TK1 expression was correlated with histological grade in DCIS and IDC patients and with pathological stage in IDC patients.
  • The degree of TK1-positive staining in the tumors of patients with ADH, DCIS and IDC was 80-90%, while the corresponding value for UDH patients was less than 5%.
  • Since the expression of TK1 varied significantly between the breast ductal subgroups, we concluded that TK1 is a reliable proliferation marker for the determination of breast tumor proliferation, particularly of pre-cancerous lesions (ADH).
  • This may enable timely treatment in the early stages of tumor development using minimal access surgery, thus avoiding extensive radical breast surgery and improving survival rates and the quality of life.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21475922.001).
  • [ISSN] 1791-3004
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


78. Hofvind S, Sørum R, Thoresen S: Incidence and tumor characteristics of breast cancer diagnosed before and after implementation of a population-based screening-program. Acta Oncol; 2008;47(2):225-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and tumor characteristics of breast cancer diagnosed before and after implementation of a population-based screening-program.
  • BACKGROUND: Randomized controlled trials and service screening programs have shown that breast cancer screening reduces the mortality from the disease.
  • The Norwegian Breast Cancer Screening Program started November 1995.
  • This study compares incidence, prognostic tumor characteristics and surgical treatment in breast cancer cases diagnosed in the pre-screening (1987-1995, n=2 618) and screening period (1996-2004, n=5 417), in women aged 50-69 years, residing in the first four counties implementing the screening program.
  • The screening period is divided into those invited versus those not invited to the screening program, and those exposed (participants) versus those not exposed to the program (non-participants).
  • RESULTS: The incidence of invasive breast cancer rose from 170 per 100 000 women years (wy) in 1987 to 355 per 100 000 wy in 1997.
  • The proportion of DCIS was 5% in the pre-screening period, and 14% in the screening period.
  • Tumors 20 mm or less were diagnosed in 56% of the invasive cases in the pre-screening period, in 74% of the invited, and in 77% of the exposed women.
  • The relative risk of diagnosing breast cancer with metastases was 0.85 (95% CI 0.84-0.87) for invited and 0.82 (95% CI 0.81-0.84) for exposed women, relative to those diagnosed in the pre-screening period.
  • Ablation was performed in 85% of the invasive cases diagnosed in the pre-screening period, and in 45% of the cases in the screening period.
  • CONCLUSION: Breast cancer diagnosed in the screening period had prognostically favorable tumor characteristics compared to breast cancer diagnosed in the pre-screening period.
  • [MeSH-major] Breast Neoplasms / epidemiology. Carcinoma, Intraductal, Noninfiltrating / epidemiology. Mass Screening

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17851868.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


79. Yang XR, Charette LA, Garcia-Closas M, Lissowska J, Paal E, Sidawy M, Hewitt SM, Rimm DL, Sherman ME: Construction and validation of tissue microarrays of ductal carcinoma in situ and terminal duct lobular units associated with invasive breast carcinoma. Diagn Mol Pathol; 2006 Sep;15(3):157-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Construction and validation of tissue microarrays of ductal carcinoma in situ and terminal duct lobular units associated with invasive breast carcinoma.
  • Construction of tissue microarrays (TMAs) to efficiently characterize large sets of noninvasive epithelial lesions in the breast by immunohistochemistry is an appealing investigative approach, but presents technical challenges.
  • We report methodologic studies performed to optimize methods for building TMAs from noninvasive breast tissues collected in a large case-control study of breast cancer.
  • Using a manual arraying technique with 2.0-mm diameter needles, we constructed TMAs from specimens obtained from 32 women with breast cancer containing the following targets:.
  • (2) 28 ductal carcinomas in situ, and (3) 23 invasive carcinomas.
  • ER/PR expression levels in multiple (up to 4) noninvasive targets of the same tissue type (TDLU or DCIS) from a single block showed good correlation.
  • These data suggest that it is feasible to produce TMAs of noninvasive breast structures, albeit with careful selection of targets, and that immunostains of such cores may permit efficient immunohistochemical characterization of peritumoral tissues.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Tissue Array Analysis / methods

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Biospecimen Research Database. Biospecimen Research Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16932071.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


80. Cody HS 3rd: Sentinel lymph node biopsy for DCIS: are we approaching consensus? Ann Surg Oncol; 2007 Aug;14(8):2179-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node biopsy for DCIS: are we approaching consensus?
  • [MeSH-major] Carcinoma, Intraductal, Noninfiltrating / surgery. Mastectomy / methods. Neoplasm Recurrence, Local / surgery. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Algorithms. Antineoplastic Agents, Hormonal / therapeutic use. Axilla / surgery. Biopsy. Combined Modality Therapy. Disease-Free Survival. False Negative Reactions. Female. Follow-Up Studies. Histocytochemistry. Humans. Immunohistochemistry. Neoadjuvant Therapy. Neoplasm Invasiveness. Prognosis. Radiotherapy. Risk Assessment. Survival Analysis. Tamoxifen / therapeutic use. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Mastectomy.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ann Surg Oncol. 2007 Aug;14(8):2202-8 [17534687.001]
  • (PMID = 17265115.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


81. van de Vijver MJ: Biological variables and prognosis of DCIS. Breast; 2005 Dec;14(6):509-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological variables and prognosis of DCIS.
  • Based on current knowledge, biological factors that have been investigated in ductal carcinoma in situ (DCIS) include histology of these lesions, the impact of margin status on local recurrence, and several genetic alterations.
  • Optimal integration of these factors in guiding optimal therapy is of great importance, since the incidence of DCIS is rising as a result of population-based mammographic screening.
  • Mastectomy will almost always cure patients with DCIS but represents overtreatment for many.
  • Less extensive treatment options should combine an optimal cosmetic result with the same safety for outcome of disease as mastectomy.
  • To guide such optimal treatment, histological classification is not sufficient and additional biological factors are being investigated for their ability to predict outcome for individual patients with DCIS.
  • In this review, the histological classification of DCIS is described and in addition the emerging knowledge on genetic alterations is summarised.
  • For clinical management of DCIS patients, genetic or other biological factors should be identified that can predict the risk of progression of DCIS to invasive breast cancer and distant metastases.
  • At present, insufficient knowledge on prognostic and predictive factors in DCIS is available.
  • Research in this area is hampered by the difficulties in obtaining DCIS tumour tissue, as the tumour cells grow in the lumen of pre-existing ducts and lobules.
  • Integration of translational studies into clinical trials aimed at optimising the treatment of DCIS are required to achieve this goal.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Breast Neoplasms / therapy. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / therapy
  • [MeSH-minor] Female. Humans. Neoplasm Invasiveness. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16246564.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 109
  •  go-up   go-down


82. Márkus B, Bajner A, Csejtei A, Firisz B, Hegedus A, Kocsis E, Kovács B, Pintér G, Tóth C: [Surgical aspects of breast cancer screening at our hospital]. Magy Seb; 2006 Oct;59(5):375-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical aspects of breast cancer screening at our hospital].
  • In addition to discussing effectiveness of breast cancer screening initiated within the National Public Health Programme, the problem of how to treat non-palpable, early invasive and in situ breast cancer (DCIS) is considered.
  • Changes in the number of surgical operations and tumour size, incidence of in situ cancer, lymph node involvement and distribution of types of surgery have been studied.
  • The number of persons participating in the screening programme has gradually increased, the number of surgical operations because of breast cancer increased from period to period.
  • Size of the detected tumours has decreased, the percentage of non-palpable cases has been significant (445 surgical interventions during the years 2002-2004: surgery: 19%).
  • The proportion of DCIS has increased to nearly four times as compared to data of years immediately preceding the era of screening (1993-1998: 11 cases, 2%; 1999-2004: 62 cases, 7.5%).
  • The proportion of breast saving surgery has increased above 50%.
  • As to the treatment of non-palpable, early invasive cancer, they underline the importance of preoperative evaluation--cytology, core biopsy--and establishing dignity.
  • In spite of the fact that the risk for potential malignancy of DCIS lesions has not yet been fully clarified, adequate treatment is indicated; the authors take stand on the issues of indication for surgery, postoperative radiotherapy and use of Tamoxifen.
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / surgery. Carcinoma, Intraductal, Noninfiltrating / epidemiology. Carcinoma, Intraductal, Noninfiltrating / surgery. Mass Screening / statistics & numerical data. Mastectomy / statistics & numerical data. Sentinel Lymph Node Biopsy / statistics & numerical data


83. Reinholz MM, Nibbe A, Jonart LM, Kitzmann K, Suman VJ, Ingle JN, Houghton R, Zehentner B, Roche PC, Lingle WL: Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer. Clin Cancer Res; 2005 May 15;11(10):3722-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer.
  • PURPOSE: We examined the feasibility of using molecular characterization of circulating tumor cells as a method for early detection of breast cancer.
  • RESEARCH DESIGN: Women without a prior history of cancer who had a breast abnormality detected on imaging followed by a breast biopsy were enrolled in this study.
  • Real-time reverse transcription-PCR was used to quantitate the expression levels of the highly breast-specific genes, mammaglobin, gamma-aminobutyric acid type A receptor pi subunit (GABA A(pi)), B305D-C, and B726P in the epithelial cell-enriched samples.
  • From their clinical assessment, 100 patients had benign breast disease, 10 patients had ductal carcinoma in situ, and 44 patients had invasive breast cancer.
  • We constructed a diagnostic test that classified patients with mammaglobin levels of at least 32.2 copies/pg beta-actin (units) in their circulating epithelial cells as positive for invasive breast cancer.
  • This resulted in a sensitivity and specificity of 63.3% and 75.0%, respectively.
  • A diagnostic test that classified patients as positive for invasive breast cancer when either mammaglobin levels were >46.3 units or B305D-C levels were >11.6 units increased the sensitivity and specificity to 70.5% and 81.0%, respectively.
  • In the latter test, 12 of the 14 node-positive breast cancer patients were correctly identified.
  • CONCLUSIONS: These results suggest that molecular characterization of circulating epithelial cells using mammaglobin and B305D-C offers potential for early detection of invasive breast cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. Gene Expression Profiling. Neoplasm Proteins / biosynthesis. Neoplastic Cells, Circulating. Uteroglobin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Mammaglobin A. Middle Aged. Neoplasm Invasiveness. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):7043; author reply 7044 [16203799.001]
  • (PMID = 15897569.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B305D-C protein, human; 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


84. Allred DC: Ductal carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monogr; 2010;2010(41):134-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal carcinoma in situ: terminology, classification, and natural history.
  • Ductal carcinoma in situ (DCIS) refers to breast epithelial cells that have become "cancerous" but still reside in their normal place in the ducts and lobules.
  • DCIS is a nonlethal type of cancer because it stays in its normal place.
  • However, DCIS is very important because it is the immediate precursor of invasive breast cancers, which are potentially lethal.
  • This article provides a general overview of DCIS, including historical perspective, methods of classification, current perspective, and future goals.
  • [MeSH-major] Breast Neoplasms / classification. Carcinoma, Intraductal, Noninfiltrating / classification
  • [MeSH-minor] Breast / ultrastructure. Calcinosis / diagnostic imaging. Cell Differentiation. Disease Progression. Epithelial Cells / pathology. Female. Humans. Mammography. Necrosis. Terminology as Topic

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20956817.001).
  • [ISSN] 1745-6614
  • [Journal-full-title] Journal of the National Cancer Institute. Monographs
  • [ISO-abbreviation] J. Natl. Cancer Inst. Monographs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  •  go-up   go-down


85. Warren JL, Weaver DL, Bocklage T, Key CR, Platz CE, Cronin KA, Ballard-Barbash R, Willey SC, Harlan LC: The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS: a population based analysis. Cancer; 2005 Nov 1;104(9):1840-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS: a population based analysis.
  • BACKGROUND: The diagnosis of ductal carcinoma in situ (DCIS) is increasing, although to the authors' knowledge there is no consensus regarding optimal treatment.
  • This analysis of women treated with breast-conserving surgery (BCS) evaluated the impact of radiation therapy (RT) in patient outcomes.
  • METHODS: The current study included a population-based sample of 1103 women residing in selected Surveillance, Epidemiology, and End Results (SEER) registries who were diagnosed with DCIS between 1991-1992.
  • Physicians were contacted in 1999 to determine whether the patient had developed a second event in the ipsilateral breast.
  • For second events, pathology reports were reviewed to determine the presence of in situ or invasive disease.
  • Cox proportional hazards and logistic regression models were used to evaluate the rates of second events and breast carcinoma deaths between women treated with and without RT.
  • Women receiving RT were significantly less likely to develop invasive breast carcinoma in the ipsilateral breast (adjusted odds ratio, 0.40).
  • By 2001, the rate of death from breast carcinoma was 2.7%; in the group of women treated with BCS only compared with 0.8% in the group of women treated with BCS with RT.
  • CONCLUSIONS: Among a population-based cohort, RT was found to significantly reduce the risk of second events in the ipsilateral breast, particularly invasive tumors, although not to the extent reported in clinical trials.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma, Intraductal, Noninfiltrating / surgery. Mastectomy, Segmental. Neoplasm Recurrence, Local
  • [MeSH-minor] Aged. Cohort Studies. Disease-Free Survival. Female. Humans. Middle Aged. Population Surveillance. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 16136599.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Burkhardt L, Grob TJ, Hermann I, Burandt E, Choschzick M, Jänicke F, Müller V, Bokemeyer C, Simon R, Sauter G, Wilczak W, Lebeau A: Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res Treat; 2010 Oct;123(3):757-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene amplification in ductal carcinoma in situ of the breast.
  • Multiple different biologically and clinically relevant genes are often amplified in invasive breast cancer, including HER2, ESR1, CCND1, and MYC.
  • To investigate their significance for tumor invasion, we compared pure ductal carcinoma in situ (DCIS) and DCIS associated with invasive cancer with regard to the amplification of these genes.
  • Fluorescence in situ hybridization (FISH) was performed on a tissue microarray containing samples from 130 pure DCIS and 159 DCIS associated with invasive breast cancer.
  • Of the latter patients, we analyzed the intraductal and invasive components separately.
  • In addition, lymph node metastases of 23 patients with invasive carcinoma were included.
  • Amplification rates of pure DCIS and DCIS associated with invasive cancer did not differ significantly (pure DCIS vs. DCIS associated with invasive cancer: HER2 22.7 vs. 24.2%, ESR1 19.0 vs. 24.1%, CCND1 10.0 vs. 14.8%, MYC 11.8 vs. 6.5%; P > 0.05).
  • Furthermore, we observed a high concordance of the amplification status for all genes if in situ and invasive carcinoma of individual patients were compared.
  • Our results indicate no significant differences between the gene amplification status of DCIS and invasive breast cancer concerning HER2, ESR1, CCND1, and MYC.
  • Therefore, our data suggest an early role of all analyzed gene amplifications in breast cancer development but not in the initiation of invasive tumor growth.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Carcinoma, Intraductal, Noninfiltrating / genetics. Gene Amplification. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Cyclin D1 / genetics. Estrogen Receptor alpha / genetics. Female. Genotype. Humans. In Situ Hybridization, Fluorescence. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Phenotype. Proto-Oncogene Proteins c-myc / genetics. Receptor, ErbB-2 / genetics. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20033484.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / Estrogen Receptor alpha; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / estrogen receptor alpha, human; 136601-57-5 / Cyclin D1; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


87. Sasano H, Suzuki T, Nakata T, Moriya T: New development in intracrinology of breast carcinoma. Breast Cancer; 2006;13(2):129-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New development in intracrinology of breast carcinoma.
  • Intratumoral metabolism and synthesis of estrogens as a result of the interactions of various enzymes are considered to play very important roles in the pathogenesis and development of hormone dependent breast carcinoma.
  • Among these enzymes, intratumoral aromatase plays as important role converting serum androgens to estrogens in situ, and serves as a source of estrogen, especially in postmenopausal patients with breast carcinoma.
  • The 17beta-hydroxysteroid dehydrogenase (17beta-HSD) isozymes catalyze the interconversion of estradiol (E2) and estrone (E1), and thereby serve to modulate the tissue levels of bioactive E2 in human breast carcinoma.
  • In human breast disease, 17beta-HSD type 1 is expressed in proliferative disease without atypia, atypical ductal hyperplasia, ductal carcinoma in situ and invasive ductal carcinoma.
  • 17Beta-HSD type 2 has not been detected in any of these breast lesions.
  • In addition, 17beta-HSD type 1 coexpression is significantly correlated with estrogen receptor status in invasive ductal carcinoma cases.
  • These results indicate that breast carcinoma can effectively convert E1, produced as a result of in situ aromatization, to E2, a biologically potent estrogen, which exerts estrogenic actions on tumor cells through estrogen receptor, especially the alpha subtype in carcinoma cells.
  • These findings also suggest that EST and STS plays important roles in regulation of in situ estrogen production, and EST especially is a potent prognostic factor in human breast carcinoma.
  • It is also important to note that the status of intratumoral aromatase, 17beta-HSD type 1, EST and STS in human breast cancer tissues is variable and not necessarily correlated with each other, which suggests different potential sources of intratumoral estrogens among individual patients with breast cancer.
  • Therefore, it will become very important to examine the intratumoral levels of 17beta-HSD type 1 and STS in the resected specimens of human breast carcinoma as potential targets of novel endocrine therapy in the near future.
  • [MeSH-major] 17-Hydroxysteroid Dehydrogenases / metabolism. Breast Neoplasms / enzymology. Estrogens / metabolism. Neoplasms, Hormone-Dependent / enzymology. Steryl-Sulfatase / metabolism. Sulfotransferases / metabolism
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Hormonal / therapeutic use. Biopsy, Needle. Disease Progression. Female. Humans. Immunohistochemistry. Middle Aged. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755106.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogens; EC 1.1.- / 17-Hydroxysteroid Dehydrogenases; EC 1.1.1.51 / 3 (or 17)-beta-hydroxysteroid dehydrogenase; EC 2.8.2.- / Sulfotransferases; EC 2.8.2.4 / estrone sulfotransferase; EC 3.1.6.2 / Steryl-Sulfatase
  • [Number-of-references] 54
  •  go-up   go-down


88. Oiso N, Kawara S, Inui H, Kawada A: Pigmented spots as a sign of mammary Paget's disease. Clin Exp Dermatol; 2009 Jan;34(1):36-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pigmented spots as a sign of mammary Paget's disease.
  • Pigmented mammary Paget's disease is a rare variant of mammary Paget's disease.
  • The clinical appearance mimics malignant melanoma.
  • The pigmented nipple was histopathologically diagnosed as mammary Paget's disease with an underlying intraductal carcinoma.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Nipples / pathology. Paget's Disease, Mammary / pathology. Pigmentation Disorders / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Skin Pigmentation Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18627392.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


89. Török K, Péley G, Mátrai Z, Bidlek M, Szabó E, Sinkovics I, Polgár C, Farkas E, Orosz Z, Köves I: [The role of sentinel lymph node biopsy in breast cancer non-invading-duct]. Magy Seb; 2006 Jun;59(3):173-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of sentinel lymph node biopsy in breast cancer non-invading-duct].
  • INTRODUCTION AND AIMS: The clinical significance of sentinel lymph node biopsy for staging patients with ductal carcinoma in situ has not yet been solved.
  • Determining the role of this method for the treatment of in situ ductal carcinoma has been the aim of this study.
  • PATIENTS AND METHOD: Dual agent guided sentinel lymph node biopsy with preoperative lymphoscintigraphy was performed on 36 patients with breast ductal carcinoma in situ from January 2001 to March 2004 at the Department of General and Thoracic Surgery, National Institute of Oncology, Budapest.
  • RESULTS: One patient has been excluded from the final analysis because of contralateral invasive breast cancer and simultaneous local recurrence in her medical history.
  • If our patient number is completed with the 5 patients operated on for ductal carcinoma in situ during the period of our feasibility study (from December 1997 to March 2000) then the rate of patients with positive sentinel lymph node(s) will be 5% (2/40).
  • Metastases were found only in patients with high risk, extended ductal carcinoma in situ who finally underwent mastectomy.
  • DISCUSSION AND CONCLUSIONS: Our results corresponds well to the international ones.
  • Performing sentinel lymph node biopsy for ductal carcinoma in situ of the breast is not recommended on the basis of the international and our own experiences.
  • In other cases when preoperative diagnostic studies do not verify invasion unequivocally we advise to perform sentinel lymph node biopsy (if necessary) after the final histological result of the excised breast specimen.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma, Intraductal, Noninfiltrating / surgery. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Lymphatic Metastasis / diagnosis. Mastectomy / methods. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16937792.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


90. Harkins LE, Matlaf LA, Soroceanu L, Klemm K, Britt WJ, Wang W, Bland KI, Cobbs CS: Detection of human cytomegalovirus in normal and neoplastic breast epithelium. Herpesviridae; 2010;1(1):8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of human cytomegalovirus in normal and neoplastic breast epithelium.
  • Breast milk is the primary route of transmission in humans worldwide, and breast epithelium is thus a likely site of persistent infection and/or reactivation, though this phenomenon has not previously been demonstrated.
  • We hypothesized that persistent HCMV infection occurs in normal adult breast epithelium and that persistent viral expression might be associated with normal and neoplastic ductal epithelium.
  • METHODS: Surgical biopsy specimens of normal breast (n = 38) breast carcinoma (n = 39) and paired normal breast from breast cancer patients (n = 21) were obtained.
  • Specimens were evaluated by immunohistochemistry, in situ hybridization, PCR and DNA sequencing for evidence of HCMV antigens and nucleic acids.
  • RESULTS: We detected HCMV expression specifically in glandular epithelium in 17/27 (63%) of normal adult breast cases evaluated.
  • In contrast, HCMV expression was evident in the neoplastic epithelium of 31/32 (97%) patients with ductal carcinoma in situ (DCIS) and infiltrating ductal carcinoma (IDC) cases evaluated (p = 0.0009).
  • CONCLUSIONS: These findings are the first to demonstrate that persistent HCMV infection occurs in breast epithelium in a significant percentage of normal adult females.
  • HCMV expression was also evident in neoplastic breast epithelium in a high percentage of normal and neoplastic breast tissues obtained from breast cancer patients, raising the possibility that viral infection may be involved in the neoplastic process.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2108-11 [10473094.001]
  • [Cites] J Virol. 2000 Sep;74(17):8028-37 [10933712.001]
  • [Cites] BMJ. 2000 Sep 9;321(7261):624-8 [10977847.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):513-8 [11229670.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3347-50 [12067971.001]
  • [Cites] Viral Immunol. 2003;16(3):231-42 [14583141.001]
  • [Cites] FEMS Microbiol Rev. 2004 Feb;28(1):59-77 [14975530.001]
  • [Cites] Cell. 2004 Aug 6;118(3):285-96 [15294155.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] J Exp Med. 2005 Feb 7;201(3):431-9 [15684322.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):211-7 [15766659.001]
  • [Cites] Breast Cancer Res. 2005;7(4):171-9 [15987472.001]
  • [Cites] J Intern Med. 2006 Mar;259(3):219-46 [16476101.001]
  • [Cites] Exp Hematol. 2006 May;34(5):555-70 [16647557.001]
  • [Cites] J Virol. 2006 Sep;80(18):9000-8 [16940512.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8960-5 [17875739.001]
  • [Cites] Neuro Oncol. 2008 Feb;10(1):10-8 [17951512.001]
  • [Cites] Curr Drug Targets. 2008 May;9(5):375-80 [18473765.001]
  • [Cites] Neoplasia. 2009 Jan;11(1):1-9 [19107226.001]
  • [Cites] Ann N Y Acad Sci. 2009 Feb;1155:206-21 [19250206.001]
  • [Cites] Cancer Res. 2009 Apr 1;69(7):2861-9 [19318580.001]
  • [Cites] Carcinogenesis. 2009 Jul;30(7):1073-81 [19468060.001]
  • [Cites] Br J Cancer. 2009 Oct 20;101(8):1351-6 [19773762.001]
  • [Cites] Cold Spring Harb Perspect Biol. 2009 Nov;1(5):a000141 [20066113.001]
  • [Cites] Cell. 2010 Mar 19;140(6):883-99 [20303878.001]
  • [Cites] Am J Pathol. 1990 Jan;136(1):23-8 [2153348.001]
  • [Cites] Cancer Res. 1995 Jan 1;55(1):39-45 [7805038.001]
  • [Cites] Microbiol Immunol. 1994;38(10):809-11 [7869960.001]
  • [Cites] Science. 1994 Jul 15;265(5170):391-4 [8023160.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2384-9 [8146127.001]
  • [Cites] J Clin Pathol. 1997 Jan;50(1):59-63 [9059359.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3937-42 [9520471.001]
  • [Cites] J Virol Methods. 1998 Feb;70(2):167-76 [9562410.001]
  • [Cites] Front Biosci. 2002 Jan 1;7:d295-306 [11779699.001]
  • [Cites] Lancet. 2002 Nov 16;360(9345):1557-63 [12443594.001]
  • [Cites] Breast Cancer Res. 2003;5(1):R13-7 [12559053.001]
  • [Cites] Breast Cancer Res. 2003;5(4):E6; author reply E7 [12817996.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):113-9 [12838311.001]
  • [Cites] Cancer Lett. 2003 Jul 30;198(1):77-81 [12893433.001]
  • [Cites] J Urol. 2003 Sep;170(3):998-1002 [12913758.001]
  • [Cites] Med Oncol. 2003;20(3):233-6 [14514972.001]
  • [Cites] Intervirology. 2004;47(1):2-13 [15044830.001]
  • [Cites] Br J Cancer. 2004 Jun 1;90(11):2149-52 [15150559.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7284-9 [15534103.001]
  • [Cites] J Med Virol. 2005 Feb;75(2):276-81 [15602723.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Dec;25(4):515-21 [17310842.001]
  • [Cites] Br J Cancer. 2009 Oct 20;101(8):1345-50 [19724278.001]
  • [Cites] J Neuroinflammation. 2010;7:16 [20205746.001]
  • [Cites] J Immunother. 2010 May;33(4):335-51 [20386472.001]
  • [Cites] Cancer Res. 2010 May 1;70(9):3576-85 [20388779.001]
  • [Cites] Sci Signal. 2010 Aug 3;3(133):ra58 [20682912.001]
  • [Cites] J Virol. 1995 Dec;69(12):7960-70 [7494309.001]
  • [Cites] J Med Virol. 1995 Sep;47(1):70-82 [8551263.001]
  • [Cites] Virology. 1996 Aug 1;222(1):293-6 [8806513.001]
  • [Cites] Microbiol Immunol. 1996;40(3):201-4 [8934674.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3341-5 [9096395.001]
  • [Cites] Med Hypotheses. 1997 Jun;48(6):491-7 [9247892.001]
  • (PMID = 21429243.001).
  • [ISSN] 2042-4280
  • [Journal-full-title] Herpesviridae
  • [ISO-abbreviation] Herpesviridae
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3063230
  •  go-up   go-down


91. Schuiling WJ, Dennesen PJ, Rinkel GJ: Extracerebral organ dysfunction in the acute stage after aneurysmal subarachnoid hemorrhage. Neurocrit Care; 2005;3(1):1-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Delayed cerebral ischemia and hydrocephalus are important intracranial secondary complications.
  • Potentially treatable extracranial complications are also frequently observed, and some are related to the occurrence of delayed cerebral ischemia and outcome.
  • This article provides an overview of the most common extracranial complications in patients with SAH and describes their effects on outcome and delayed cerebral ischemia.
  • [MeSH-minor] Brain Ischemia / etiology. Heart Diseases / classification. Heart Diseases / etiology. Hemodynamics. Humans. Hydrocephalus / etiology. Inflammation. Lung Diseases / classification. Lung Diseases / etiology. Ventricular Dysfunction, Left / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Cardiol. 2000 Oct;36(4):1328-35 [11028491.001]
  • [Cites] Am Rev Respir Dis. 1981 Dec;124(6):718-22 [7316276.001]
  • [Cites] Am Heart J. 1993 Jul;126(1):235-40 [8322676.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1995 May;58(5):614-7 [7745412.001]
  • [Cites] Neurosurgery. 2002 Apr;50(4):749-55; discussion 755-6 [11904025.001]
  • [Cites] Neurocrit Care. 2004;1(2):157-70 [16174911.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):28-37 [9420069.001]
  • [Cites] J Neurosurg. 2002 Mar;96(3):510-4 [11883835.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(1):87-93 [9522914.001]
  • [Cites] Surg Neurol. 1987 Mar;27(3):253-8 [3810457.001]
  • [Cites] Keio J Med. 2000 Feb;49 Suppl 1:A151-3 [10750369.001]
  • [Cites] Crit Care Med. 1995 Jun;23(6):1007-17 [7774210.001]
  • [Cites] Anesth Analg. 1999 Oct;89(4):962-4 [10512272.001]
  • [Cites] J Am Coll Cardiol. 1988 Sep;12(3):600-5 [3403818.001]
  • [Cites] Neurology. 1993 Apr;43(4):712-8 [8469328.001]
  • [Cites] Crit Care Med. 2004 Mar;32(3):832-8 [15090970.001]
  • [Cites] Can J Neurol Sci. 1989 Aug;16(3):299-304 [2766122.001]
  • [Cites] Surg Neurol. 2001 Jan;55(1):12-6; discussion 16 [11248297.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3):602-6; discussion 606-7 [10981747.001]
  • [Cites] Chest. 1997 May;111(5):1326-33 [9149590.001]
  • [Cites] Stroke. 2002 Jun;33(6):1671-6 [12053010.001]
  • [Cites] Intensive Care Med. 1996 Jul;22(7):672-6 [8844233.001]
  • [Cites] J Neurosurg Anesthesiol. 1999 Jul;11(3):209-13 [10414679.001]
  • [Cites] Neurosurgery. 2003 May;52(5):1025-31; discussion 1031-2 [12699543.001]
  • [Cites] Neurology. 2001 May 22;56(10):1299-304 [11376177.001]
  • [Cites] J Neurosurg. 2003 Apr;98 (4):741-6 [12691398.001]
  • [Cites] J Neurosurg. 1993 Dec;79(6):885-91 [8246057.001]
  • [Cites] Mayo Clin Proc. 2004 Aug;79(8):992-1000 [15301325.001]
  • [Cites] Br J Anaesth. 1991 Jul;67(1):58-63 [1859761.001]
  • [Cites] Acta Neurochir (Wien). 1995;133(3-4):141-6 [8748756.001]
  • [Cites] Resuscitation. 2002 Sep;54(3):255-8 [12204458.001]
  • [Cites] Stroke. 2000 Apr;31(4):901-6 [10753996.001]
  • [Cites] J Neurosurg Sci. 1987 Apr-Jun;31(2):45-8 [3668657.001]
  • [Cites] Crit Care Med. 1989 Apr;17(4):381 [2702846.001]
  • [Cites] Stroke. 2004 Feb;35(2):548-51 [14739408.001]
  • [Cites] Neurol Med Chir (Tokyo). 1997 Dec;37(12):881-4; discussion 884-5 [9465585.001]
  • [Cites] Clin Neurol Neurosurg. 2000 Jun;102(2):78-83 [10817893.001]
  • [Cites] J Neurosurg. 2003 Mar;98(3):524-8 [12650423.001]
  • [Cites] Crit Care Med. 1999 Mar;27(3):505-14 [10199529.001]
  • [Cites] Crit Care. 2003 Jun;7(3):R7-R12 [12793884.001]
  • [Cites] J Neurosurg. 1990 Jul;73(1):18-36 [2191090.001]
  • [Cites] Stroke. 2002 May;33(5):1225-32 [11988595.001]
  • [Cites] Neurology. 2003 Oct 28;61(8):1132-3 [14581680.001]
  • [Cites] J Cardiol. 1990;20(2):359-67 [2104411.001]
  • [Cites] Neurology. 1994 May;44(5):815-20 [8190280.001]
  • [Cites] Neurosurgery. 1996 Jan;38(1):152-60 [8747964.001]
  • [Cites] Neurosurgery. 1989 Aug;25(2):161-5 [2770982.001]
  • [Cites] Stroke. 2001 Sep;32(9):1989-93 [11546886.001]
  • [Cites] Jpn J Med. 1991 Mar-Apr;30(2):142-5 [1865586.001]
  • [Cites] Clin Cardiol. 1997 Apr;20(4):402-3 [9098603.001]
  • [Cites] Stroke. 1999 Jul;30(7):1402-8 [10390314.001]
  • [Cites] Int J Cardiol. 1994 Oct;46(3):289-91 [7814185.001]
  • [Cites] J Neurosurg. 2003 Jun;98 (6):1222-6 [12816268.001]
  • [Cites] J Neurosurg. 1980 Mar;52(3):295-301 [7359184.001]
  • [Cites] Surg Neurol. 1979 May;11(5):349-56 [441925.001]
  • [Cites] N Engl J Med. 2001 Nov 8;345(19):1359-67 [11794168.001]
  • [Cites] Circulation. 1993 Jul;88(1):101-6 [8319322.001]
  • [Cites] Arch Intern Med. 1987 Mar;147(3):591-2 [3827438.001]
  • [Cites] J Am Soc Echocardiogr. 2000 Aug;13(8):774-9 [10936822.001]
  • [Cites] Ann Neurol. 1985 Feb;17(2):137-40 [3977297.001]
  • [Cites] J Neurosurg. 1995 Nov;83(5):889-96 [7472560.001]
  • [Cites] Neurosurgery. 2004 Jun;54(6):1369-73; discussion 1373-4 [15157293.001]
  • [Cites] J Neurosurg. 1978 Oct;49(4):502-7 [690677.001]
  • [Cites] Lancet. 1992 Jan 4;339(8784):68 [1346000.001]
  • [Cites] Chest. 1982 Mar;81(3):318-20 [7056107.001]
  • [Cites] Neurol Med Chir (Tokyo). 2001 Nov;41(11):529-34; discussion 534-5 [11758704.001]
  • [Cites] Schweiz Med Wochenschr. 1992 May 16;122(20):751-7 [1604280.001]
  • [Cites] Hum Pathol. 1986 Jan;17(1):9-13 [2417934.001]
  • [Cites] Ann Neurol. 1985 Aug;18(2):211-6 [4037761.001]
  • [Cites] Neurosurgery. 1986 Aug;19(2):300-4 [3528910.001]
  • [Cites] Jpn Heart J. 1999 Nov;40(6):683-701 [10737553.001]
  • [Cites] Acta Neurochir (Wien). 2003 Mar;145(3):195-9; discussion 199 [12632115.001]
  • [Cites] J Neurosurg. 1991 Aug;75(2):308-11 [2072171.001]
  • [Cites] Neurosurgery. 2003 Feb;52(2):276-81; discussion 281-2 [12535355.001]
  • [Cites] N Engl J Med. 1983 Dec 8;309(23 ):1414-9 [6314140.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Jan;25(1):126-9 [14729541.001]
  • [Cites] BMJ. 1996 Sep 14;313(7058):681-3 [8811765.001]
  • [Cites] Stroke. 1999 Apr;30(4):780-6 [10187879.001]
  • [Cites] Ann Neurol. 1990 Jan;27(1):106-8 [2301918.001]
  • [Cites] Am J Med. 1979 Jul;67(1):32-8 [463915.001]
  • [Cites] Stroke. 1987 May-Jun;18(3):558-64 [3590246.001]
  • [Cites] Neurosurgery. 1989 Nov;25(5):762-8 [2586729.001]
  • [Cites] Surg Neurol. 1984 Feb;21(2):132-4 [6701748.001]
  • [Cites] J Electrocardiol. 2002;35 Suppl:257-62 [12539136.001]
  • [Cites] N Engl J Med. 2005 Feb 10;352(6):539-48 [15703419.001]
  • (PMID = 16159088.001).
  • [ISSN] 1541-6933
  • [Journal-full-title] Neurocritical care
  • [ISO-abbreviation] Neurocrit Care
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 85
  •  go-up   go-down


92. Israel PZ, Vicini F, Robbins AB, Shroff P, McLaughlin M, Grier K, Lyden M: Ductal carcinoma in situ of the breast treated with accelerated partial breast irradiation using balloon-based brachytherapy. Ann Surg Oncol; 2010 Nov;17(11):2940-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal carcinoma in situ of the breast treated with accelerated partial breast irradiation using balloon-based brachytherapy.
  • BACKGROUND: We reviewed our institution's experience treating patients with ductal carcinoma in situ (DCIS) of the breast with balloon-based accelerated partial breast irradiation (APBI) to determine the efficacy of this treatment approach in this group of patients.
  • MATERIALS AND METHODS: A total of 126 cases of DCIS seen and treated with APBI using balloon-based brachytherapy constitute the study population.
  • The median age at diagnosis was 59 years (range, 37-82) with 21% younger than age 50.
  • Of these patients, 86% had estrogen receptor positive DCIS.
  • All patients were treated with 34 Gy in 10 fractions using either the MammoSite™ or Contura™ breast brachytherapy catheter.
  • RESULTS: With a median follow-up of 24 months (range, 0.7-73.9), three (2.4%) ipsilateral breast tumor recurrences (IBTRs) developed for a 2-year actuarial rate of 0.81%.
  • With a median follow-up of 40 months (range, 15.6-73.9), one IBTR developed for a 3-year actuarial rate of 2.15%.
  • CONCLUSIONS: Early results in patients with DCIS treated with APBI using balloon-based brachytherapy produced results similar to those with invasive cancer treated with APBI or DCIS treated with whole breast irradiation.
  • [MeSH-major] Brachytherapy / methods. Breast Neoplasms / radiotherapy. Carcinoma, Intraductal, Noninfiltrating / radiotherapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20443148.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Masroor I: Prediction of benignity or malignancy of a lesion using BI-RADS. J Coll Physicians Surg Pak; 2005 Nov;15(11):686-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of benignity or malignancy of a lesion using BI-RADS.
  • OBJECTIVE: To determine the Positive Predictive Value (PPV) of the Breast Imaging Reporting and Data System (BI-RADS) categories as confirmed by histopathology of localized lesion.
  • PLACE AND DURATION OF STUDY: All patients undergoing mammographic needle localizations for breast lesions from January 2001 to December 2003 were included in the study.
  • In a total of 111 patients, 114 mammographically-guided needle localizations were performed for breast lesions.
  • In all these patients the mammographic finding and BI-RADS category were recorded.
  • RESULTS: In 114 localizations the histopathologic finding showed 25 (22%) cancers (10 [40%] were ductal carcinoma in situ (DCIS); (15 [60 %] were invasive cancers) and 89 (78 %) benign lesions.
  • One case of cancer in this group was DCIS.
  • [MeSH-major] Breast Neoplasms / classification. Breast Neoplasms / radiography. Mammography

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16300702.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


94. Gupta S, Joshi K, Wig JD, Arora SK: High frequency of loss of allelic integrity at Wilms' tumor suppressor gene-1 locus in advanced breast tumors associated with aggressiveness of the tumor. Indian J Cancer; 2009 Oct-Dec;46(4):303-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High frequency of loss of allelic integrity at Wilms' tumor suppressor gene-1 locus in advanced breast tumors associated with aggressiveness of the tumor.
  • BACKGROUND: The product of Wilms' tumor suppressor gene (WT1), a nuclear transcription factor, regulates the expression of the insulin-like growth factor (IGF) and transforming growth factor (TGF) systems, both of which are implicated in breast tumorigenesis and are known to facilitate angiogenesis.
  • In the present study, WT1 allelic integrity was examined by Loss of Heterozygosity (LOH) studies in infiltrating breast carcinoma (n=60), ductal carcinoma in situ (DCIS) (n=10) and benign breast disease (n=5) patients, to determine its possible association with tumor progression.
  • METHODS: LOH at the WT1 locus (11p13) as determined by PCR-RFLP for Hinf1 restriction site and was subsequently examined for its association with intratumoral expression of various growth factors i.e.
  • TGF-beta1, IGF-II, IGF-1R and angiogenesis (VEGF and Intratumoral micro-vessel density) in breast carcinoma.
  • RESULTS: Six of 22 (27.2%) genetically heterozygous of infiltrating breast carcinoma and 1 of 4 DCIS cases showed loss of one allele at WT1 locus.
  • Histologically, the tumors with LOH at WT1 were Intraductal carcinoma (IDC) and were of grade II and III.
  • The expression of factor IGF-II and its receptor, IGF-1R was significantly higher in carcinoma having LOH at WT1 locus.
  • A positive correlation was observed between the TGF-beta1, VEGF expression and IMD scores in infiltrating carcinoma.
  • CONCLUSIONS: The current study indicates that the high frequency of loss of allelic integrity at Wilms' tumor suppressor gene-1 locus in high-graded breast tumors is associated with aggressiveness of the tumor.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / pathology. Genes, Wilms Tumor
  • [MeSH-minor] Carcinoma in Situ / genetics. Carcinoma in Situ / pathology. Humans. Insulin-Like Growth Factor II / biosynthesis. Loss of Heterozygosity. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length. Receptor, IGF Type 1 / biosynthesis. Transforming Growth Factor beta1 / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19749460.001).
  • [ISSN] 1998-4774
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta1; 0 / Vascular Endothelial Growth Factor A; 67763-97-7 / Insulin-Like Growth Factor II; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


95. Liu F, Cui L, Zhang Y, Chen L, Wang Y, Fan Y, Lei T, Gu F, Lang R, Pringle GA, Zhang X, Chen Z, Fu L: Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma. Breast Cancer Res Treat; 2010 Dec;124(3):677-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
  • HAb18G is a recently identified hepatoma-associated antigen and its association with tumor growth, invasion, and angiogenesis has been studied in a variety of tumors.
  • However, its role in the tumor progression of breast cancer has not been explored.
  • HAb18G expression was examined by immunohistochemistry in pathological sections of 1,637 breast tissue samples and by in situ hybridization in 41 cases of invasive breast carcinomas (BC).
  • While not detected in any cases of tumor-like conditions or benign tumors of breast, and only rarely in normal tissue (4.4%), HAb18G expression was gradually up-regulated from atypical ductal hyperplasia (27.3%), to ductal carcinoma-in situ (59.8%), and to BC (61.4%) (P < 0.01).
  • Significant differences of expression were also identified among the subgroups of BC examined: in decreasing order from invasive micropapillary carcinoma, ductal carcinoma, lobular carcinoma, papillary carcinoma, medullary carcinoma, to mucinous adenocarcinoma (P = 0.001), corresponding to their known clinical aggressiveness.
  • We also demonstrated that up-regulated tumor expression of HAb18G was a significant predictor of reduced disease progression-free survival rate and a shorter overall survival, independent of systemic therapies.
  • Further evaluation of this new marker in breast cancer is indicated.
  • [MeSH-major] Antigens, CD147 / analysis. Biomarkers, Tumor / analysis. Breast Neoplasms / immunology. Carcinoma / immunology. Carcinoma, Intraductal, Noninfiltrating / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. China. Disease-Free Survival. Female. Humans. Immunohistochemistry. In Situ Hybridization. Kaplan-Meier Estimate. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Retrospective Studies. Time Factors. Treatment Outcome. Up-Regulation. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20213083.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BSG protein, human; 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 136894-56-9 / Antigens, CD147; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


96. Quan ML, Hodgson N, Lovrics P, Porter G, Poirier B, Wright FC: National adoption of sentinel node biopsy for breast cancer: lessons learned from the Canadian experience. Breast J; 2008 Sep-Oct;14(5):421-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] National adoption of sentinel node biopsy for breast cancer: lessons learned from the Canadian experience.
  • Sentinel lymph node biopsy (SLNB) in breast cancer has not been readily adopted into Canadian surgical practice in comparison with the United States.
  • We sought to evaluate current national practice patterns and explore barriers to direct efforts to improve the adoption of SLNB in Canada.
  • Of the 506 (57%) surgeons who treated breast cancer, half were community based with breast surgery comprising <25% of their practices.
  • Most (70%) performed <or=5 breast surgeries/month.
  • Predictors of performing SLNB were breast/oncology fellowship (p = 0.03) or greater percentage of practice dedicated to breast (p = 0.02) but not region, type of practice (community versus academic), gender or year of residency completion.
  • The majority (75%) performed SLNB as a stand-alone procedure for T1/T2 cancers and high-risk ductal carcinoma in situ (70%).
  • [MeSH-major] Attitude of Health Personnel. Breast Neoplasms / pathology. Clinical Competence. Neoplasm Staging / methods. Sentinel Lymph Node Biopsy / statistics & numerical data

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18657140.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Vergouwen MD, Vermeulen M, van Gijn J, Rinkel GJ, Wijdicks EF, Muizelaar JP, Mendelow AD, Juvela S, Yonas H, Terbrugge KG, Macdonald RL, Diringer MN, Broderick JP, Dreier JP, Roos YB: Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke; 2010 Oct;41(10):2391-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group.
  • BACKGROUND AND PURPOSE: In clinical trials and observational studies there is considerable inconsistency in the use of definitions to describe delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage.
  • A major cause for this inconsistency is the combining of radiographic evidence of vasospasm with clinical features of cerebral ischemia, although multiple factors may contribute to DCI.
  • METHODS: An international ad hoc panel of experts involved in subarachnoid hemorrhage research developed and proposed a definition of DCI to be used as an outcome measure in clinical trials and observational studies.
  • RESULTS: It is proposed that in observational studies and clinical trials aiming to investigate strategies to prevent DCI, the 2 main outcome measures should be:.
  • (1) cerebral infarction identified on CT or MRI or proven at autopsy, after exclusion of procedure-related infarctions; and (2) functional outcome.
  • Secondary outcome measure should be clinical deterioration caused by DCI, after exclusion of other potential causes of clinical deterioration.
  • Vasospasm on angiography or transcranial Doppler can also be used as an outcome measure to investigate proof of concept but should be interpreted in conjunction with DCI or functional outcome.
  • CONCLUSIONS: The proposed measures reflect the most relevant morphological and clinical features of DCI without regard to pathogenesis to be used as an outcome measure in clinical trials and observational studies.
  • [MeSH-major] Brain Ischemia / etiology. Subarachnoid Hemorrhage / complications

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20798370.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501444; United States / NINDS NIH HHS / NS / P50 NS05597701A2; United States / NINDS NIH HHS / NS / P50NS035966
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


98. Yen TW, Kuerer HM, Ottesen RA, Rouse L, Niland JC, Edge SB, Theriault RL, Weeks JC: Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ. J Clin Oncol; 2007 Aug 1;25(22):3251-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ.
  • PURPOSE: The National Surgical Adjuvant Breast and Bowel Project B-24 trial, published in June 1999, demonstrated that tamoxifen after breast-conserving surgery (BCS) and radiotherapy for ductal carcinoma in situ (DCIS) reduced the absolute occurrence of ipsilateral and contralateral breast cancer.
  • We assessed the impact of B-24 on practice patterns at selected National Comprehensive Cancer Network (NCCN) centers.
  • PATIENTS AND METHODS: Tamoxifen use after surgery was examined among 1,622 patients presenting for treatment of unilateral DCIS between July 1997 and December 2003 at eight NCCN centers.
  • Factors significantly associated with receipt of tamoxifen included diagnosis on or after July 1, 1999 (odds ratio [OR], 3.85; P < .0001), BCS in patients younger than 70 years (OR, 3.21; P = .0073), no history of cerebrovascular or peripheral vascular disease (OR, 3.13; P = .0071), receipt of radiotherapy (OR, 1.82; P = .0009), and previous hysterectomy (OR, 1.34; P = .0459).
  • CONCLUSION: Tamoxifen use after surgery for DCIS at NCCN centers increased after presentation of the B-24 results.
  • Rates varied substantially by institution, suggesting that physicians differ in how they weigh the modest reduction in breast cancer risk with tamoxifen against its potential adverse effects in this population.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma in Situ / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Outcome Assessment (Health Care). Practice Patterns, Physicians'. Randomized Controlled Trials as Topic. Tamoxifen / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577019.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


99. Gupta VK: Magnesium for delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: time for a paradigm shift? Stroke; 2005 Dec;36(12):2530
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnesium for delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: time for a paradigm shift?
  • [MeSH-major] Brain Ischemia / prevention & control. Intracranial Aneurysm / drug therapy. Magnesium Sulfate / therapeutic use. Neuroprotective Agents / therapeutic use. Subarachnoid Hemorrhage / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Aneurysm.
  • Hazardous Substances Data Bank. MAGNESIUM SULFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304138.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke; a journal of cerebral circulation
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neuroprotective Agents; 7487-88-9 / Magnesium Sulfate
  •  go-up   go-down


100. Neira P, Aguirre B, Taub T, Gutiérrez L, Sáez C, Ibarra A, Silva C: [Breast MRI--histologic correlation for ductal carcinoma in situ]. Radiologia; 2009 Jul-Aug;51(4):396-402
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast MRI--histologic correlation for ductal carcinoma in situ].
  • [Transliterated title] Carcinoma ductal in situ: correlación entre la histología y la resonancia magnética de mama.
  • OBJECTIVE: To evaluate the concordance between the breast MRI findings and the histologic findings for the size and extension of pure ductal carcinoma in situ (DCIS) and to compare this concordance with that of conventional techniques (mammography and ultrasonography).
  • MATERIAL AND METHODS: This is a retrospective study of consecutive patients diagnosed with DCIS after percutaneous biopsy.
  • Finally, we determined the impact of the MRI findings on the surgical management of patients with DCIS.
  • MRI overestimated the size of DCIS by a mean of 3 mm, whereas mammography and ultrasonography underestimated it by 9 mm and 18 mm, respectively.
  • CONCLUSION: Breast MRI is better than conventional techniques for the evaluation of the size of DCIS.
  • Breast MRI also detects more cases of multifocality and multicentricity.
  • We recommend that all patients diagnosed with DCIS (especially those with dense breasts) undergo breast MRI prior to surgery.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19406443.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down






Advertisement